Document:

Exhibit 10.22b

 

Confidential material appearing in this document
has been omitted and filed separately with the Securities and Exchange Commission in accordance with Rule 24b-2, promulgated under
the Securities and Exchange Act of 1934, as amended. Omitted information has been replaced with asterisks.

 

LEASE AGREEMENT FOR A GAMMA KNIFE
UNIT 

(PERFEXION UPGRADE)

 

This LEASE
AGREEMENT FOR A GAMMA KNIFE UNIT (PERFEXION UPGRADE) (this "Agreement") is dated effective July 30, 2013 (the "Effective
Date"), and is entered into by and between TUFTS MEDICAL CENTER, INC., a not-for-profit Massachusetts corporation (formerly
known as New England Medical Center Hospitals, Inc.) ("Medical Center"), and GK FINANCING, LLC, a California limited
liability company ("GKF").

 

Recitals:

 

A.           GKF
and Medical Center entered into a Lease Agreement for a Gamma Knife Unit dated October 5, 1998, which was amended by a certain
Addendum to Lease Agreement for a Gamma Knife Unit dated effective April 1, 2005 (collectively, the "Prior Lease"). Pursuant
to the Lease, GKF is leasing to Medical Center a Leksell Stereotactic Gamma Knife unit, Model 4C (the “Model 4C”).

 

B.           On
February 28, 2008, Medical Center changed its name from New England Medical Center Hospitals, Inc. to Tufts Medical Center, Inc.

 

C.           The
parties intend to upgrade the Model 4C to a Leksell Gamma Knife Perfexion which will be equipped with new cobalt-60 (the "Equipment"
or "Perfexion") which will be leased by GKF to Medical Center pursuant to the terms and conditions of this Agreement.

 

Agreement:

 

NOW,
THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.          Lease.
Subject to and in accordance with the covenants and conditions set forth in this Agreement, GKF hereby leases to Medical Center,
and Medical Center hereby leases from GKF, the Equipment. The Equipment to be leased to Medical Center pursuant to this Agreement
shall include the latest approved Gamma Knife technology available as of the date of this Agreement, including all hardware and
software related thereto as listed in the Specifications.

 

2.          Execution
of LGK Agreement by and between Medical Center and Elekta. Medical Center agrees that simultaneously with the execution of
this Agreement it shall execute that certain LGK Agreement with Elekta, (hereinafter referred to as the "LGK Agreement"),
a copy of which is attached hereto as Exhibit 1 and incorporated herein by this reference. GKF hereby grants to Medical Center
a non-exclusive right and sublicense to use the "LGP Software" as defined in and contemplated under, and subject to the
terms and conditions of, the LGK Agreement.

 

    	1

    	 

    

 

3.           Perfexion
Upgrade.

 

3.1           Subject
to the terms and conditions set forth below, GKF, at GKF's cost and expense, shall upgrade the Model 4C to the Equipment described
in Recital C above (the "Perfexion Upgrade"). GKF shall be responsible for all third party costs related to installation
and rigging associated with the Perfexion and de-installation of the Model 4C. In connection with the Perfexion Upgrade, GKF shall
also upgrade the flooring and painting in the Medical Center gamma knife suite. In connection with the Perfexion Upgrade, Medical
Center, at Medical Center's cost and expense, shall provide GKF with Medical Center personnel (including Medical Center physicists)
and services upon request and as required by GKF, among other things, to oversee, supervise and assist with construction and compliance
with local, state and federal regulatory requirements and with nuclear regulatory compliance issues and the calibration of the
Perfexion, and modification of the Determination of Need, as necessary. Subject to Medical Center's compliance with Section 3.2
below, GKF shall use commercially reasonable efforts to perform the Perfexion Upgrade in the Fall of 2013. The Parties agree that,
once the Model 4C is no longer operable due to the commencement of de-installation, GKF will use commercially reasonable efforts
to complete the installation and rigging of the Perfexion within six (6) weeks (the “Down Period”) so as to minimize
the interruption of Medical Center’s services to its patients. GKF will provide Medical Center with not less than sixty (60)
days notice of the approximate dates of the Down Period so that Medical Center can appropriately manage patient scheduling.

 

3.2           Notwithstanding
the foregoing, the Perfexion Upgrade shall be performed by GKF only after all licenses, permits, approvals, consents and authorizations
necessary and appropriate for the Perfexion Upgrade, including, without limitation, the proper handling of the cobalt-60 (collectively,
the "Permits"), have been obtained by Medical Center at Medical Center's sole cost and expense (other than any filing
or registration fees which shall be paid for by GKF). The timing and procedure for such Perfexion Upgrade shall be as mutually
agreed upon between the parties. Medical Center represents and warrants to GKF that the Site and shielding in the vault for the
Perfexion are compliant with all applicable Nuclear Regulatory Commission and other federal and state requirements.

 

3.3           GKF
confirms and warrants that the Perfexion fits into the existing footprint of the Model 4C, that there is no need for construction
at the site (other than minor modifications to be made by GKF as needed), and that Medical Center’s site meets all requirements
of the Site Planning Criteria, as that term is used in the purchase agreement between Elekta, Inc. and GKF; provided that, in so
warranting, GKF relies upon the warranties and representations made by Medical Center under the Prior Lease and in this Agreement,
including without limitation, Section 3.2 above (all of which representations and warranties shall survive and remain in full force
and effect).

 

    	2

    	 

    

 

3.4           Medical
Center warrants that it shall utilize its best efforts to fulfill on an expeditious basis its obligations under this Section 3.
Medical Center further warrants that it shall on a regular basis keep GKF informed of Medical Center's progress in fulfilling its
obligations pursuant to this Section 3.

 

3.5           Upon
receipt of Elekta’s report on the results of the Acceptance Tests (as defined in the LGK Agreement), Medical Center shall
have three (3) business days to review and validate the results of the Acceptance Tests to confirm that the Perfexion meets the
manufacturer’s specifications and documentation. If Medical Center fails to respond within such three (3) business day period,
Medical Center shall be deemed to have validated and confirmed the results of the Acceptance Tests.

 

3.6           It
is understood by the parties that GKF is not responsible for any additional upgrades, hardware, cobalt reloading, software changes
and/or other modifications to the Perfexion except as expressly set forth herein or otherwise agreed upon in writing by Medical
Center and GKF.

 

3.7           Unless
Medical Center notifies GKF at least one hundred eighty (180) days prior to the expiration of the Term that Medical Center wishes
to further extend the Term of its Lease Agreement with GKF upon such terms as shall be mutually agreed upon in writing between
the parties, GKF shall remove the Perfexion, at its sole expense, within ninety (90) days after the expiration of the Term.

 

3.8           Notwithstanding
anything to the contrary set forth in this Agreement, (i) GKF shall de-install, remove and retain all ownership rights and title
to the existing Model 4C; (ii) GKF shall acquire and hold title to the Perfexion; and (iii) Medical Center shall have no ownership
interest (or option to purchase any ownership interest) in the Model 4C and/or the Perfexion.

 

3.9           On
the date on which the Model 4C is no longer operable due to the commencement of its de-installation (the “Early Termination
Date”), the Prior Lease shall be terminated and of no further force and effect; provided, however, that those provisions
of the Prior Lease that are expressly stated or intended to survive termination of the Prior Lease shall survive and remain applicable
beyond the Early Termination Date.

 

4.           Additional
Services of GKF.

 

4.1           GKF
shall provide maintenance and service of the Equipment as needed for the term of this Agreement to keep the Equipment in a good
state of repair, reasonable wear and tear excepted, including but not limited to providing a minimum of two PMI (Preventative Maintenance
Inspections) per year and repair work as needed. GKF agrees to exercise due and proper care in the repair and maintenance of the
Equipment. GKF shall have the right of access to the Equipment for the purpose of inspecting same at all reasonable times and upon
reasonable notice. In the event the Equipment is improperly used by Medical Center or its employees, agents, officers and physicians,
GKF may service or repair the same as needed and such expense shall be paid by Medical Center, unless the repair is covered by
the Repair Service Agreement, if any, referenced in Section 17, below.

 

4.2           Use
of the calibration phantom system by the Medical Center as requested by the Medical Center, based on availability.

 

    	3

    	 

    

 

4.3           Training
of Medical Center staff on the proper use of the Equipment (i) at the time of installation of the Perfexion and (ii) at the request
of Medical Center for the term of this Agreement, such requests not to exceed more than one request annually;

 

4.4           Upon
the termination of this Agreement, the de-installation and removal of the Perfexion, including any third party costs (but excluding
Medical Center costs). Medical Center, at Medical Center's cost and expense, shall provide GKF with Medical Center personnel (including
Medical Center physicists) and services upon request and as required by GKF to oversee, supervise and assist with such de-installation
and removal.

 

5.            [Intentionally
omitted.]

 

6.            Term
of the Agreement. The initial term of this Agreement (the "Term") shall commence as of the Effective Date and, unless
earlier terminated or extended in accordance with the provisions of this Agreement, shall continue until the date that is six (6)
years after the date on which the first procedure using the Perfexion is performed at the Site (the "First Procedure Date").
Medical Center's obligation to make the rental payments to GKF for the Equipment as described in Paragraph 7 below shall commence
on the first day of the first full month after the Effective Date of this Agreement. The rental payments described in Paragraph
7 shall apply to the Model 4C until such time as it is upgrade to the Perfexion, and shall then continue to apply to the Perfexion
for the duration of the Term of this Agreement.

 

7.            Per
Procedure Payments. Medical Center shall pay to GKF the applicable per procedure payment as specified in Exhibit 2 for the
use of the Equipment, subject to adjustment as set forth in Sections 7.1(a) and 7.1(b) below. A "procedure" shall be
defined as a single patient treatment session using the Equipment provided by GKF pursuant to this Agreement, that may include
one or more isocenters during that session. Medical Center shall be billed on the fifteenth (15th) and the last day of each month
for the actual number of procedures performed during the first and second half of the month, respectively. Medical Center shall
pay for the procedures invoiced within thirty (30) days after being invoiced.

 

The parties acknowledge
that the compensation payable by Medical Center for the Perfexion as set forth in this Agreement has been negotiated by the parties
at arm’s length based upon reasonable and jointly derived assumptions regarding the capacity for clinical services available
from the Perfexion, Medical Center’s capabilities in providing high quality radiation oncology services, market dynamics,
GKF’s risk in providing the Perfexion, and the provision to GKF of a reasonable rate of return on its investment in support
of the Perfexion. Based thereon, the parties believe that the rent payments represent fair market value for the use of the Perfexion,
the de-installation and removal of the Model 4C, the Perfexion upgrade, maintenance and service, personal property taxes, cost
of insurance coverage for the Perfexion, and any other additional services and costs to be provided or paid for by GKF pursuant
to this Agreement. Medical Center undertakes no obligation to perform any minimum number of procedures on the Perfexion, and the
use of the Perfexion for the performance of procedures is wholly based upon the independent judgment of physicians who order such
procedures to meet the medical needs of their patients.

 

    	4

    	 

    

 

(a)          If
at any time or from time-to-time after the Effective Date, the Medical Center’s Commercial Rate with any "Designated
Payor" (excluding those covered in 7(b) below), is increased or decreased such that the new Commercial Rate for such Designated
Payor is greater or less than the "Base Commercial Rate" for that Designated Payor (or the then current Commercial Rate
if the Non-Medicare Fee Per Procedure rates shown in Exhibit 2 for such Designated Payor have previously been revised pursuant
to this subsection) by *, then, (1) Medical Center shall notify GKF thereof in writing (but without disclosing the identity of
the Designated Payor) within thirty (30) days of any such increase or decrease and shall provide GKF with reasonably sufficient
documentation evidencing the revised Commercial Rate for that Designated Payor (and the amount of the increase or decrease), including,
without limitation, copies of the applicable contractual language or fee schedule (with the identity of the Designated Payor redacted),
and any remittance advices, EOBs or other documentation showing the payments made to Medical Center by such Designated Payor immediately
before and after the subject increase or decrease to its Commercial Rate, it being understood that such documentation may become
available following the effective date of such increase or decrease and that Medical Center shall provide such documentation to
GKF as and when available; (2) effective in the next billing cycle after said notification (provided that such increase or decrease
to the Commercial Rate is then effective), the fee for procedures performed on patients who are assigned to or enrolled with such
Designated Payor shall be equal to the Non-Medicare Fee Per Procedure rates as shown in Exhibit 2 (or the then current Non-Medicare
Fee Per Procedure rates for such Designated Payor if said Non-Medicare Fee Per Procedure rates have previously been revised pursuant
to this subsection), increased or decreased therein by * of the dollar-for-dollar increase or decrease to the Commercial Rate for
that Designated Payor; and (3) the Non-Medicare Fee Per Procedure rates set forth in Exhibit 2 for all other Designated Payors
shall remain unchanged and in full force and effect. For example, if a Designated Payor’s Commercial Rate decreases by *
from the Base Commercial Rate (which, for purposes of this example, is assumed to exceed the * threshold above), then, each Non-Medicare
Fee Per Procedure rate shown in Exhibit 2 for that Designated Payor shall be decreased by *.

 

(b)          If
at any time or from time-to-time after the Effective Date, the "Medicare Rate" is increased or decreased such that the
new Medicare Rate is greater or less than the "Base Medicare Rate" (or the then current Medicare rate if the Medicare
Fee Per Procedure rates shown in Exhibit 2 have previously been revised pursuant to this subsection) by * or more, then, (1) Medical
Center shall notify GKF thereof in writing within thirty (30) days of any such increase or decrease and shall provide GKF

 

(c)          with
reasonably sufficient documentation evidencing the revised Medicare Rate (and the amount of the increase or decrease), including,
without limitation, copies of the applicable contractual language or fee schedule (with the identity of the Designated Payor redacted),
and any remittance advices, EOBs or other documentation showing the payments made to Medical Center immediately before and after
the subject increase or decrease to its Medicare Rate, it being understood that such documentation may become available following
the effective date of such increase or decrease and that Medical Center shall provide such documentation to GKF as and when available;
(2) effective in the next billing cycle after said notification (provided that such increase or decrease to the revised Medicare
Rate is then effective), the fee for procedures performed on Medicare patients shall be equal to the Medicare Fee Per Procedure
rates as shown in Exhibit 2 (or the then current Medicare Fee Per Procedure rates if said Medicare Fee Per Procedure rates have
previously been revised pursuant to this subsection), increased or decreased therein by * of the dollar-for-dollar increase or
decrease to the Medicare Rate. For example, if the Medicare Rate increases by * over the Base Medicare Rate (which, for purposes
of this example, is assumed to exceed the * threshold above), then, each Medicare Fee Per Procedure rate shown in Exhibit 2 shall
be increased by *.

 

    	5

    	 

    

 

(d)          Notwithstanding
anything to the contrary set forth in this Agreement, and in addition to GKF's termination rights set forth in Section 18 below,
GKF shall have the right in its sole and absolute discretion to terminate this Agreement upon ninety (90) days prior written notice
to Medical Center if, as a result of any actual or impending decrease to the Commercial Rates and/or the Medicare Rates, GKF projects
that the sum of all per procedure payments made by Medical Center to GKF under this Agreement during the next succeeding twelve
(12) month period will fall short of $750,000 in the aggregate.

 

(e)          As
used herein:

 

(i)          "Base
Commercial Rate" shall mean the Medical Center’s Commercial Rate for the applicable Designated Payor (excluding
Medicare) as of the Effective Date of this Agreement.

 

(ii)         "Base
Medicare Rate" shall mean the Medical Center’s Medicare Rate as of the Effective Date of the Agreement.

 

(iii)        "Commercial
Rate" shall mean Medical Center's contracted reimbursement rate then in effect with a Designated Payor for the technical
component of all services (including, but not limited to, treatment planning and delivery, but excluding codes specifically related
to physics support) related to a procedure performed on the Equipment, including, without limitation, all adjustments and other
amounts payable to, or entitled to be collected by, Medical Center or its representatives or affiliates from such Designated Payor.

 

(iv)        "Designated
Payor" shall mean the payors listed on Exhibit 3 attached hereto.

 

(v)         "Medicare
Rate" shall mean the aggregate Medicare fee-for-service reimbursement rate for the technical component of all services
(including, but not limited to, treatment planning and delivery, but excluding codes specifically related to physics support) related
to a procedure performed on the Equipment using CPT code 77371, defined as Stereotactic Radiosurgery Gamma, or any substitutions,
replacements and/or supplements thereto (or, if no longer in effect, their respective outpatient rate replacements for Gamma Knife
procedures), taking into account, without limitation, any and all new codes, repeals, modifications, changes in interpretation
and other adjusting factors, which reimbursement rates are payable to, or entitled to be collected by, Medical Center or its representatives
or affiliates from any and all Medicare-related payor sources, including, without limitation, carriers, fiscal intermediaries and
any other Medicare-related third party payors. Medical Center represents and warrants to GKF that the difference between the Medicare
Rate in effect immediately prior to the Effective Date and the Medicare Rate in effect as of the Effective Date is approximately
$4,600.

 

    	6

    	 

    

 

8.           Use
of the Equipment. The Equipment may be used by Medical Center only at the Site and shall not be removed therefrom. Medical
Center shall not assign or sublease the Equipment or its rights hereunder without the prior written consent of GKF; which consent
shall not be unreasonably withheld. No permitted assignment or sublease shall relieve Medical Center of any of its obligations
hereunder. Medical Center shall not use nor permit the Equipment to be used in any manner nor for any purpose for which, in the
reasonable opinion of Elekta or GKF based on current medical practice, the Equipment is not designed or reasonably suitable. Medical
Center shall not permit any liens, whether voluntary or involuntary, to attach to the Equipment, without the prior written consent
of GKF. Medical Center shall have no interest in the Equipment other than the rights acquired as a lessee hereunder and the Equipment
shall remain the property of GKF regardless of the manner in which it may be installed or attached at the Site. Medical Center
shall, at GKF's request, affix to the Equipment tags, decals, or plates furnished by GKF, indicating GKF's ownership of the Equipment.

 

9.           Additional
Covenants of Medical Center. In addition to the other covenants made by Medical Center, Medical Center shall at its own cost
and expense:

 

9.1           Provide
properly trained professional, technical and support personnel and supplies required for the timely scheduling and treatment of
patients utilizing the Equipment.

 

9.2           Assume
all medical and financial responsibility for the overseers' monitoring of all patients' medical condition and treatment.

 

9.3           Fully
comply with all of its obligations under the LGK Agreement that affect the operation of the Equipment and/or that affect this Agreement.

 

9.4           Upon
request by GKF and at GKF’s reasonable expense, Medical Center shall execute and deliver a commercially reasonable form of
consent to sublease, subordination or other documentation if such a document is reasonably requested by the third party financing
company which holds a security interest in the Perfexion.

 

10.          Additional
Covenants. Representations and Warranties of GKF. In addition to the other covenants, representations and warranties, made
by GKF in this Agreement:

 

10.1         GKF
represents and warrants that GKF has full power and authority to enter into this Agreement, and that this Agreement does not and
will not violate any agreement, contract or instrument binding upon GKF.

 

10.2         GKF
represents and warrants to Medical Center that, upon delivery of the Equipment to Medical Center, GKF shall use its best faith
efforts to require that Elekta meets its contractual obligations to GKF and puts the Equipment, as soon as possible, into good,
safe and serviceable condition and fit for its intended use in accordance with the manufacturer's specifications, guidelines and
field modification instructions.

 

    	7

    	 

    

 

10.3         GKF
represents and warrants that throughout the term of this Agreement, Medical Center shall enjoy the use of the Equipment, free of
the rights of any other persons except for those rights reserved by GKF under this Agreement or granted to Elekta under the LGK
Agreement.

 

11.         Indemnification.

 

11.1         Each
party shall indemnify, defend and hold harmless the other party, and such other party’s directors, officers, employees, agents
and affiliates, from and against any and all claims, actions, liabilities, costs and expenses (including without limitation judgment
and settlement costs, court costs and attorneys’ fees) arising out of or relating to negligent or intentional acts or omissions
of the indemnifying party or any failure by the indemnifying party to perform any obligation or covenant of the indemnifying party
in this Agreement

 

11.2         Medical
Center shall further indemnify GKF for any damage to the Equipment to the extent such damage is caused by the negligent or willfully
wrongful acts or omissions of Medical Center or its agents, officers, physicians and employees and are not covered and reimbursed
by GKF’s insurance. In the event the Equipment is destroyed or rendered unusable as a result of such negligent or willfully
wrongful acts or omissions, this indemnification shall extend up to (but not exceed) the full replacement value of the Equipment
at the time of its destruction less salvage value, if any.

 

11.3         GKF
shall further indemnify Medical Center in the event that Medical Center suffers any loss, damage, claim or expense solely as the
result of GKF’s breach of its obligations under Section 17, below.

 

12.          Ownership/Title.
It is expressly understood that Medical Center shall acquire no right, title or interest in or to the Equipment, other than the
right to the possession and use of the same in accordance with the terms of this Agreement.

 

GKF may at its sole
discretion finance the Equipment. Financing may be in the form of an installment loan or a capitalized lease or other commercially
available debt instrument. Should GKF finance the Equipment through an installment loan, GKF shall be required to provide the Equipment
as collateral against the loan. Should GKF finance the Equipment through a capitalized lease title shall vest with the lessor until
GKF exercises its buy-out option. In addition, should GKF finance the Equipment, said agreement may be used as collateral against
the loan. No financing by GKF will relieve GKF of its obligations to Medical Center or materially change Medical Center's duties
or materially increase the burdens or risks imposed on Medical Center. Medical Center's interest under this Agreement shall be
subject and subordinate to the interests of the Lender, which Medical Center shall promptly confirm in writing on Lender's form,
if requested by GKF.

 

13.          Cost
of Use of the Equipment. Except as is otherwise provided herein, Medical Center shall bear the entire cost of using the Equipment
during the Term of this Agreement. This shall include, but not be limited to, providing trained professionals, technical and support
personnel and supplies to properly operate the Equipment. Medical Center shall be fully responsible and liable for all acts and/or
omissions of such professional, technical and support personnel.

 

    	8

    	 

    

 

14.         Taxes.
GKF shall pay any personal property taxes levied against the Equipment and any other taxes or governmental fees or assessments,
however denoted, whether of the federal government, any state government or any local government, levied or based on this Agreement
or the use of the Equipment except for those taxes, if any, pertaining to the gross income or gross receipts of Medical Center.

 

15.         [Intentionally
omitted.]

 

16.         [Intentionally
omitted.]

 

17.         Repair
Service Agreement. GKF may at its discretion enter into a Repair Service Agreement with Elekta. If GKF has entered into a Repair
Service Agreement with Elekta, (a) GKF agrees to fulfill all of its obligations under the Repair Service Agreement and acknowledges
that Medical Center is a third party beneficiary of the Repair Service Agreement; (b) GKF will reasonably pursue any and all remedies
it may have against Elekta under the Repair Service Agreement, if any, to insure that the Equipment will be in conformity with
Elekta's warranties so that it is free from defects in design, materials, workmanship or manufacture which result in noncompliance
with the Specifications and/or Elekta's warranties to GKF; provided that, for the avoidance of doubt, none of the foregoing obligations
in this Section shall be binding upon GKF if GKF has not entered into a Repair Service Agreement with Elekta.

 

18.         Termination.
If, after the initial twenty-four (24) month period following the First Procedure Date or any subsequent 12 month period, the sum
of all per procedure payments made by Medical Center to GKF under this Agreement during the most recent twelve (12) month period
fell short of $750,000, then and in that event, GKF shall have the option (but not the obligation) of terminating this Agreement
upon the giving of written notice to Medical Center of said termination not less than one hundred and eighty (180) days prior to
GKF's designated termination date. GKF shall remove the Equipment, at its sole expense, within ninety (90) days after the designated
termination date, unless Medical Center notifies GKF within ninety (90) days following receipt of GKF's notice of termination that
it wishes to purchase the Equipment in cash at a price to be mutually agreed upon by the parties.

 

19.         Option
to Extend Agreement.

 

19.1         At
the end of the initial Term, Medical Center shall have the option to:

 

(a)          Renegotiate
this Agreement for a five year renewal term, or

 

(b)          Terminate
this Agreement. If Medical Center terminates this Agreement at the end of the initial Term, Medical Center shall have the option
to purchase the Equipment in cash at a price to be mutually agreed upon by the parties. Medical Center shall exercise such option
by giving written notice to GKF not less than ninety (90) days prior to the expiration of the initial Term. If Medical Center does
not issue such notice, Medical Center shall be deemed to have elected not to exercise such option, and GKF shall remove the Equipment,
at its sole cost and expense, within ninety (90) days after the expiration of the initial Term.

 

    	9

    	 

    

 

Medical Center shall
exercise one (1) of the two (2) options referred to above by mailing an irrevocable written notice thereof to GKF at Four Embarcadero
Center, Suite 3700, San Francisco, California, 94111, by registered mail, postmarked on or before the end of the year immediately
preceding the expiration of the initial Term of this Agreement. Any such notice shall be sufficient if it states in substance that
Medical Center elects to exercise its option and states which of the two (2) options referred to above Medical Center is exercising.

 

20.         No
Warranties by GKF with Respect to the Equipment. GKF SUPPLIES THE EQUIPMENT "AS IS" AND NOT BEING THE MANUFACTURER
OF THE EQUIPMENT OR THE MANUFACTURER'S AGENT, MAKES NO WARRANTY OR REPRESENTATION, EITHER EXPRESSED OR IMPLIED, AS TO THE EQUIPMENT'S
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, DESIGN, CONDITION, DURABILITY, CAPACITY, MATERIAL OR WORKMANSHIP OR AS TO PATENT
INFRINGEMENT OR THE LIKE, it being agreed that all such risks as between GKF and Medical Center, shall be borne by Medical Center.
Medical Center agrees to look solely to the manufacturer (Elekta) or to suppliers of the Equipment (and its software) for any and
all warranty claims with respect to the Equipment. Any and all warranties made by Elekta to GKF will be in its good faith best
efforts enforced by GKF on behalf of Medical Center during the initial Term hereof and any renewal Terms. Medical Center agrees
that GKF shall not be responsible for the operation of the Equipment. GKF shall not be responsible for any direct or indirect consequential
loss or damage resulting from the installation, operation or use of the Equipment or otherwise. Medical Center expressly waives
any right to hold GKF liable hereunder for any claims, demands and liabilities arising out of or in connection with the design,
manufacture, possession or operation of the Equipment.

 

21.         Events
of Default by Medical Center and Remedies. The occurrence of any one of the following shall constitute an Event of Default
by Medical Center hereunder:

 

(a)          Medical
Center fails to pay any installment of semi-monthly procedure payments when due when such default continues for a period of thirty
(30) days after notice thereof from GKF or its assignee is given to Medical Center;

 

(b)          Medical
Center attempts to remove, sell, transfer, encumber, sublet or part with possession of the Equipment or any items thereof, except
as expressly permitted herein;

 

(c)          Medical
Center shall fail to observe or perform any of the other obligations required to be observed or performed by Medical Center hereunder
and such failure shall continue uncured for sixty (60) days after written notice thereof to Medical Center by GKF;

 

(d)          Medical
Center ceases doing business as a going concern, makes an assignment for the benefit of creditors, admits in writing its inability
to pay its debts as they become due, files a voluntary petition in bankruptcy, is adjudicated a bankrupt or an insolvent, files
a petition seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar arrangement
under any present or future statute, law or regulation or files an answer admitting the material allegations of a petition filed
against it in any such proceeding, consents to or acquiesces in the appointment of a trustee, receiver, or liquidator of it or
of all or any substantial part of its assets or properties, or it or its shareholders shall take any action looking to its dissolution
or liquidation.

 

    	10

    	 

    

 

(e)          Within
sixty (60) days after the commencement of any proceedings against Medical Center seeking reorganization, arrangement, readjustment,
liquidation, dissolution or similar relief under any present or future statute, law or regulation, such proceedings shall not have
been dismissed, or if within thirty (30) days after the appointment without Medical Center's consent or acquiescence of any trustee,
receiver or liquidator of it or of all or any substantial part of its assets and properties, such appointment shall not be vacated.

 

Upon the occurrence of
an Event of Default by Medical Center, GKF may at its option do any or all of the following: (i) by written notice to Medical Center,
terminate this Agreement as to the Equipment in default, wherever situated, and for such purposes, enter upon the Site without
liability for so doing or GKF may cause Medical Center and Medical Center hereby agrees to return the Equipment to GKF at Medical
Center's sole cost and expense; and (ii) sell, dispose of, hold, use or lease the Equipment in default, as GKF in its sole discretion
may determine (and GKF shall not be obligated to give preference to the sale, lease or other disposition of the Equipment over
the sale, lease or other disposition of similar Equipment owned or leased by GKF). In any event, Medical Center shall, without
further demand, pay to GKF an amount equal to all sums due and payable for all periods up to and including the date on which GKF
had declared this Agreement to be in default.

 

Medical Center agrees
that GKF shall have no obligation to sell the Equipment. Medical Center shall in any event remain fully liable for reasonable damages
as provided by law for all costs and expenses incurred by GKF on account of such default, including but not limited to, all court
costs and reasonable attorneys' fees. The rights afforded GKF hereunder shall not be deemed to be exclusive, but shall be in addition
to any other rights or remedies provided by law.

 

22.         Events
of Default by GKF and Remedies. The occurrence of any one of the following shall constitute an Event of Default by GKF hereunder:

 

(a)          GKF
shall fail to observe or perform any of the obligations required to be observed or performed by GKF hereunder and such failure
shall continue uncured for sixty (60) days after written notice thereof to GKF by Medical Center;

 

(b)          GKF
ceases doing business as a going concern, makes an assignment for the benefit of creditors, admits in writing its inability to
pay its debts as they become due, files a voluntary petition in bankruptcy, is adjudicated a bankrupt or an insolvent, files a
petition seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution or similar arrangement
under any present or future statute, law or regulation or files an answer admitting the material allegations of a petition filed
against it in any such proceeding, consents to or acquiesces in the appointment of a trustee, receiver, or liquidator of it or
of all or any substantial part of its assets or properties, or it or its shareholders shall take any action looking to its dissolution
or liquidation.

 

    	11

    	 

    

 

(c)          Within
sixty (60) days after the commencement of any proceedings against GKF seeking reorganization, arrangement, readjustment, liquidation,
dissolution or similar relief under any present or future statute, law or regulation, such proceedings shall not have been dismissed,
or if within thirty (30) days after the appointment without GKF's consent or acquiescence of any trustee, receiver or liquidator
of it or of all or any substantial part of its assets and properties, such appointment shall not be vacated.

 

Upon the occurrence of
an Event of Default by GKF, Medical Center may at its option do any or all of the following: (i) by written notice to GKF, terminate
this Agreement and, in such event, GKF shall remove the Equipment at GKF's sole cost and expense or, in the absence of removal
by GKF within ninety (90) days after a written request therefor, Medical Center may remove the Equipment with all due care and
store the Equipment at GKF's sole cost and expense, or (ii) purchase the Equipment in cash at a price to be mutually agreed upon
by the parties.

 

GKF shall in any event
remain fully liable for reasonable damages as provided by law for all costs and expenses incurred by Medical Center on account
of such default, including but not limited to all court costs and reasonable attorney's fees. The rights afforded Medical Center
hereunder shall not be deemed to be exclusive, but shall be in addition to any other rights or remedies provided by law.

 

23.         Insurance.

 

23.1         During
the Term of this Agreement (and any successive terms) GKF shall, at its own cost and expense, keep in effect an all risk and hazard
insurance policy covering the Equipment. The all risk and hazard insurance policy shall be for an amount not less than the replacement
cost of the Equipment. During the Term of this Agreement, Medical Center shall, at its own cost and expense, keep in effect public
liability and professional liability insurance policies concerning the operation of the Equipment by Medical Center. Said policies
shall be in the amounts of not less than $1,000,000 per occurrence and $5,000,000 in aggregate per year. Medical Center and GKF,
their successors and assigns, shall be named as additional insureds and/or loss payees on the insurance policies maintained hereunder
by the other party. Evidence of such insurance coverages shall be furnished by both parties to the other party upon written request,
by no later than the Delivery Date.

 

23.2         If
the Equipment is rendered unusable as a result of any physical damage to, or destruction of, the Equipment, Medical Center shall
give to GKF immediate notice. GKF shall determine, within thirty (30) days after the date of occurrence of such damage or destruction,
whether the Equipment can be repaired. In the event GKF determines that the Equipment cannot be repaired, GKF at its sole cost
and expense shall promptly replace the Equipment subject to availability and subject, further, to Medical Center's obligations
under Section 11.2 above. This Agreement shall continue in full force and effect as though such damage or destruction had not occurred.
In the event GKF determines that the Equipment can be repaired, GKF shall cause the Equipment to be promptly repaired at its sole
expense, subject, however, to Medical Center's obligations under Section 4.1 above.

 

24.         Notices.
Any notices required under this Agreement shall be sent in writing and shall be deemed to have been duly given if delivered by
hand or mailed by certified or registered mail to the following addresses:

 

    	12

    	 

    

 

To GKF:     GK
Financing, LLC

Craig K. Tagawa,
C.E.O.

Four Embarcadero
Center, Suite 3700

San Francisco,
CA 94111

 

To Medical
Center:    Tufts Medical Center, Inc.

750 Washington
Street

NEMC 428

Boston, MA
02111

 

Or to such other addresses
as either party may specify for the reception of notice from time to time in writing to the other party.

 

25.         Integration/Supersedure.
This Agreement contains the full and entire Agreement between the parties hereto, and no oral or written understanding is of any
force or effect whatsoever unless expressly contained in a writing executed subsequent to the date of this Agreement.

 

26.         Waivers.
To the extent that either party fails or chooses not to pursue any of its remedies under this Agreement or pursuant to applicable
law, such shall not prejudice such party's rights to pursue any of those remedies at any future time and shall not constitute a
waiver of such party's rights.

 

27.         Assignments.
This Agreement is binding upon and shall inure to the benefit of the permitted successors or assigns of the respective parties
hereto, except that neither party may assign its rights or obligations under this Agreement without the express written consent
of the other (which consent shall not be unreasonably withheld or delayed).

 

28.         Amendments.
This Agreement shall not be amended or altered in any manner unless such amendment or alteration is in a writing signed by both
parties.

 

29.         Record-Keeping
Requirements.

 

29.1         Medical
Center and GKF shall generate such records and make such disclosures as may be required, from time to time, by the Medicare, Medicaid
and other third party payment programs with respect to this Agreement in order to meet all requirements for participation and payment
associated with such programs, including but not limited to the matters covered by Section 1861(v)(1)(I) of the Social Security
Act.

 

29.2         For
the purpose of compliance with Section 1861(v)(1)(I) of the Social Security Act, as amended, and any regulations promulgated pursuant
thereto, both parties agree to comply with the following statutory requirements (a) until the expiration of four (4) years after
the termination of this Agreement, both parties shall make available, upon written request to the Secretary of Health and Human
Services or, upon request, to the Comptroller General of the United States, or any of their duly authorized representatives, the
contract, and books, documents and records of such party that are necessary to certify the nature and extent of such costs, and
(b) if either party carries out any of the duties of the contract through a subcontract with a value or cost of $10,000 or more
over a twelve month period, with a related organization, such subcontract shall contain a clause to the effect that until the expiration
of four (4) years after the furnishing of such services pursuant to such subcontract, the related organization shall make available,
upon written request to the Secretary, or upon request to the Comptroller General, or any of their duly authorized representatives
the subcontract, and books, documents and records of such organization that are necessary to verify the nature and extent of such
costs.

 

    	13

    	 

    

 

30.         Supplier
and Owner of Perfexion. The parties hereto agree that, notwithstanding anything to the contrary set forth herein, the Lease
is and shall be treated and interpreted as a "finance lease," as such term is defined in Article 2A of the Uniform Commercial
Code, that GKF shall be treated as a finance lessor who is entitled to the benefits and releases from liability accorded to a finance
lessor under Article 2A of the Uniform Commercial Code. In furtherance of the foregoing, Medical Center acknowledges that, before
signing this Agreement, GKF has informed Medical Center in writing (a) that Elekta is the entity supplying the Perfexion, (b) that
Medical Center is entitled (under Section 2A of the Uniform Commercial Code) to the promises and warranties, including those of
any third party, provided to GKF by Elekta which is the entity supplying the goods in connection with or as part of the contract
by which GKF acquired the Perfexion or the right to possession and use of the Perfexion, and (c) that Medical Center may communicate
with Elekta and receive an accurate and complete statement of those promises and warranties, including any disclaimers and limitations
of them or of remedies. Medical Center also acknowledges that Medical Center has selected Elekta to supply the Perfexion and has
directed GKF to acquire the Perfexion or the right to possession and use of the Perfexion from Elekta. Nothing herein shall be
construed to limit GKF’s obligations and responsibilities under this Agreement.

 

31.         Miscellaneous
Provisions.

 

31.1         The
invalidity or unenforceability of any portion or provision of this Agreement shall not effect the validity or enforceability of
any other portion, nor shall either party's implied or express consent to the breach or waiver of any provision of this Agreement
constitute a waiver of such provision as to any subsequent breach.

 

31.2         In
the event of any claim or controversy arising hereunder, the prevailing party in such claim or controversy shall be entitled to
a reasonable attorneys' fee in addition to whatever other relief said party would be otherwise entitled.

 

31.3         Force
Majeure. Failure to perform by either party will be excused in the event of any delay or inability to perform its duties under
this Agreement directly or indirectly caused by conditions beyond its reasonable control including without limitation, fires, floods,
earthquakes, snow, ice, disasters, Acts of God, accidents, riots, wars, operation of law, strikes, governmental action or regulations,
shortages of labor, fuel, power, materials, manufacturer delays or transportation problems.

 

31.4         This
Agreement may be executed in separate counterparts, each of which when so executed and delivered shall be an original, but all
of which counterparts shall together constitute the same instrument. The captions and paragraph headings used herein are for convenience
only and shall not be used in construing or interpreting this Agreement. This Agreement constitutes the full and complete agreement
and understanding between the parties hereto concerning the subject matter hereof and shall supersede any and all prior written
and oral agreements with regard to such subject matter.

 

    	14

    	 

    

 

31.5         Notwithstanding
anything to the contrary set forth in this Agreement, nothing set forth in this Agreement shall limit, impair or otherwise affect
the respective rights, obligations and remedies of the parties under the Prior Lease, provided however that the pricing terms of
the Prior Lease shall be replaced by Section 7 and Exhibit 2 of this Agreement, and provided further that, subject to Section 3.9
above, the Prior Lease shall terminate on the date of the de-installation of the Model 4C.

 

IN WITNESS WHEREOF,
the parties have signed this Agreement on the day and year first above written.

 

	GKF:	Medical Center:
	 	 
	GK FINANCING, LLC	TUFTS MEDICAL CENTER, INC.
	 	 
	By:	/s/ Ernest A. Bates, MD	By:	/s/ Okey Agba
	Name:	Ernest A. Bates, MD	Name:	Okey Agba
	Title:	Policy Committee Member	Title:	Chief Financial Officer

 

    	15

    	 

    

 

 

Exhibit 1

 

LGK AGREEMENT

 

    	16

    	 

    

 

 

Prepared for

 

TUFTS MEDICAL CENTER

750 WASHINGTON ST STE 1012

BOSTON, MA 02111-1526

 

JUNE 28, 2012

 

    	17

    	 

    

 

LEKSELL GAMMA KNIFE® END USER AGREEMENT

 

THIS AGREEMENT is entered into as of the
1st day of July, 2012 by and between ELEKTA, INC., a corporation organized and existing under the laws of Georgia (hereinafter
referred to as “Elekta”), and Tufts Medical Center,. (hereinafter referred to as “End User”).

 

WITNESSETH:

 

WHEREAS, Elekta has agreed to sell the “Leksell
Gamma Knife®” system (hereinafter defined and referred to as the “LGK®”) to GK Financing, LLC.. hereinafter
referred to as “Buyer”), and

 

WHEREAS, Buyer has agreed to lease the LGK®
to End User under separate agreement.

 

WHEREAS, Elekta and End User wish to enter
this Agreement for their mutual benefit;

 

NOW THEREFORE, in consideration of the mutual covenants and
obligations, warranties and indemnities herein contained and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto agree as follows:

 

ARTICLE I. DEFINED TERMS. 

 

The following words and terms shall have the meanings
set forth opposite them in this Article I:

 

Acceptance Tests are
those tests which demonstrate that the LGK® meets the manufacturer’s specification and which are defined in the Purchase
Agreement between Buyer and Elekta.

Charging means all handling
of the Cobalt Supply at the Site and the installation of such Cobalt Supply in the LGK®.

Cobalt Supply means the
supply of the Cobalt-60 sources to be installed in the LGK®.

Effective Date is the
date of execution of this Agreement by the End User, as indicated in this Agreement.

Hardware shall mean that
computer hardware and related equipment described in the Specification.

Lease Agreement shall
mean the Agreement between Buyer and End User pursuant to which Buyer shall lease the LGK® to End User.

LGK®  is the device,
which is technically specified in Exhibit A hereto, to be sold, delivered, and installed by Elekta at the Site.

LGP Software means the
dose planning software for the LGK®, which is described in the Specification.

Site shall mean that
location described on the Exhibit B hereto.

Site Planning Criteria
are the requirements which the Site must meet to properly accommodate the LGK® and are defined in the Purchase Agreement between
Elekta and Buyer.

Specification refers
to the technical standards with which the LGK® shall comply, as described in Exhibit A hereto.

 

ARTICLE II. PERMITS 

 

2.1          Permits. End User shall obtain
any license (the “User License”) from the Nuclear Regulatory Commission (or relevant state agency if the Site is located
in an “Agreement State”) authorizing it to take possession of the Cobalt Supply and shall obtain such other licenses,
permits, approvals, consents and authorizations which may be required by local governmental or other regulatory agencies for the
Site, its preparation, the charging of the LGK® with its Cobalt Supply, the conduct of Acceptance Tests, and the use of the
LGK®. End User shall not run, operate, or otherwise use the LGK®, except for the purpose of conducting the Acceptance Tests,
until the Acceptance Tests have been successfully completed.

 

ARTICLE III. OPERATION AND TRAINING. 

 

3.1         Operation. End User warrants
and covenants that the LGK® shall not be run, operated or otherwise used, except by and to qualified employees or physicians,
who are suitably skilled and experienced to use the LGK®.

3.2          Technical Training. Elekta shall
provide to four (4) persons on the End User’s staff instruction relating to the technical operation and maintenance of the
LGK. Such instruction shall not exceed two consecutive days and will be provided on site by installation personnel at the time
of install.

3.3          Introductory Clinical Training. Introductory
Clinical Training Program. Indications, Technique, Literature, etc. Length of training is 5 consecutive days. Up to four (4) training
spaces included (Tuition only). May be substituted for Technical/Applications training course at Elekta Sweden as noted on Exhibit
A.

3.4          Post Clinical Start Up Site Visit.
Elekta shall provide a one-day site visit from one Clinical Applications representative. The visit must be arranged within 3-6
months post clinical start up. The commitment will expire thereafter unless documented alternate arrangements are made. The purpose
is to ensure the customer is comfortable using all features in the Leksell GammaPlan® PFXTM software.

3.5          LGK® Software. Elekta hereby
consents to Buyer’s sublicense to End User of the LGK® Software, to be utilized only for the purpose of planning dosages
of treatments to be performed with the LGK®. A copy of the LGK® Software License from Elekta to Buyer is attached hereto
as Exhibit D End User agrees that its sublicense to the LGK® Software shall be subject to the terms and conditions of Exhibit
D hereto. End User agrees, in favor of Elekta, to perform the obligations assigned to Buyer in Exhibit D hereto. In the event the
sublicense of the LGK® Software from

 

    	18

    	 

    

 

Buyer to End User is terminated due to an act or omission of
Buyer and without fault of the End User, then End User shall have the right to obtain from Elekta a direct royalty-free license
to utilize the LGK® Software on the terms and conditions described in Exhibit D hereto.

3.6.         Intellectual Property.

(a)         End User hereby
acknowledges that the trademarks Gamma Knife® and Leksell Gamma Knife® (collectively, the “Mark”) are protected
by United States federal registrations and the Mark constitutes valuable intellectual property of an affiliate of Elekta in which
it has established substantial goodwill. End User hereby acknowledges that proper use of the Mark in any advertising of End User’s
own surgical services performed with the LGK® surgical instrument is highly important to maintaining such value and goodwill.

(b)         Subject to the
terms and conditions of this section, Elekta, as agent for Elekta Instrument, S.A. of Geneva, Switzerland, the owner of the Mark,
hereby grants End-User a non-exclusive, royalty-free license without right to sublicense solely for the purpose of using the Mark
in connection with the promotion and advertising of any of End User’s own services to be performed by use of the LGK®
surgical instrument.

(c)         End User, in the conduct of End User’s
business, is strictly prohibited from using the Mark in or as its official legal name. However, End User may use the trademark
as part of the following fictitious trade name:

 

“Gamma Knife® Center of Tufts Medical Center”

 

As long as End User
utilizes a fictitious trade name which includes the Mark, End User shall not perform radiosurgical services with any equipment
other than the LGK®. If End User performs any radiosurgical service with any equipment other than the LGK® or if End User
ceases to perform radiosurgical services with the LGK®, End User shall immediately cease utilizing the Mark as part of its
fictitious trade name. Notwithstanding the foregoing, and for the avoidance of doubt, End User shall be entitled to use the Elekta
Axesse system to perform radiological services at Tufts Medical Center.

(d)         In advertising,
references to the Mark must include the registration symbol ® and such symbol must be used at least once per piece of advertising
material along with the words “Gamma Knife® and Leksell Gamma Knife® are U.S. federally registered trademarks of
Elekta Instrument S.A.., Geneva, Switzerland” somewhere in the advertisement. Elekta reserves the right to require End User
to discontinue the use of advertising that does not conform to such requirements.

(e)         End User may
use the words “Gamma Knife® Center of [add distinctive name]” as part of any internet domain name, or URL,
telephone number or other communications address or symbol provided that the full name, “Gamma Knife® Center of [add
distinctive name]” is used. User may use a variation or abbreviation of such term only after obtaining Elekta’s
prior written consent to the proposed use in question. User may not under any circumstances, use the words “gamma
Knife® ” alone, for any internet domain name, or URL, telephone number or other communications address or symbol.

(f)          All advertising or promotional materials
in which the mark is utilized shall comply with all applicable laws and regulations as well as the standards of proper advertising.

(g)         Elekta shall have the right to terminate
the license granted in this section with immediate effect if End User violates any provision of this section or utilizes the Mark
in any manner which, in the sole opinion of Elekta, presents a reasonable possibility of damage to the Mark.

(h)         Upon termination of the license granted
by this section, End User shall immediately cease all use of the mark, including, but not limited to, the use permitted under subsection
(e) of this section.

(i)          Buyer acknowledges
that a breach of any of its covenants or agreements hereunder will cause immediate and irreparable harm to Elekta and Elekta Instrument
S.A. End User acknowledges and agrees that no adequate remedy at law exists for any such breach, and End User agrees that in the
event of such a breach Elekta shall be entitled to injunctive relief and such other relief as any court with jurisdiction may deem
just and proper.

 

ARTICLE IV. CONFIDENTIALITY

 

4.1          End User shall treat and maintain
as confidential all technical information and know-how to it pursuant to this Agreement (including LGK® Software), except for
know-how specifically designated as non-confidential pursuant to this Agreement or otherwise so designated by the Elekta. End User
shall not disclose any aspect of such know-how (including the LGK® Software) to any other Person, including any corporation
or governmental or quasi-governmental agency; provided that, End User shall have the right to disclose such know-how to its employees
and resident physicians to the extent necessary for use of the LGK®, but End User shall be responsible to ensure that such
know-how is not disclosed by such persons.

4.2         The provisions of this Article IV
shall survive the termination of this Agreement and shall apply with equal force to any technical information or know-how concerning
the LGK® acquired by End User other than pursuant to this Agreement.

4.4         The obligations of confidentiality
and restriction of access pursuant to this Article IV shall not apply to any trade secret or confidential information that was
(a) in the public domain at the time of such access or subsequently came in to the public domain through no fault of the Person
subject to the provisions of Article IV; (b) rightfully known to the Person given such access prior to such access or developed
independently by the Person given such access; (c) received by the Person given such access as a matter of right from a source
other than a Person subject to the provisions of this Article IV; or (d) required to be disclosed by subpoena or court order, but
Buyer shall give immediate notice of such subpoena or court order to Elekta and shall request the court to grant confidential treatment
to the confidential information disclosed pursuant to such subpoena or court order.

 

ARTICLE V. WARRANTY AND REPAIR SERVICE
AGREEMENT

 

5.1         Elekta provides the warranty for the LGK® set forth
in Exhibit C hereto.

 

ARTICLE VI. EXCUSABLE DELAYS

 

If the performance of this Agreement by
Elekta or Buyer or any obligation of Elekta or Buyer hereunder is prevented, restricted or interfered with by reason of fire, explosion,
acts of God, labor disputes or accidents affecting performance under this Agreement, or war, mobilization, civil commotions, blockade
or embargo, or any law, regulation, ordinance or requirement of any government or regulatory agency, or any other act whatsoever
similar to those above enumerated, or any other circumstance being beyond the reasonable control of Elekta or Buyer, then and in
that event Elekta or Buyer, as the case may be, shall promptly notify the other parties hereto of the resulting difficulties therefrom,
and any of the foregoing events shall excuse any performance required under this Agreement.

 

    	19

    	 

    

ARTICLE VII. LIMITATION OF LIABILITY; INDEMNIFICATION.

 

7.1         The exclusive remedies of End User
and Elekta’s sole liabilities for breaches of this Agreement shall be limited to those specifically provided for in Section
5.1 (and Exhibit E hereto) and in this Article VII. In no event shall Elekta be liable to End User for loss of use, revenue or
profit, or for any other direct, indirect, incidental or consequential damage, whether arising in contract or tort.

7.2         Elekta shall defend and indemnify
End User and its Affiliates, agents, servants and employees, and hold them harmless from and against all damages, claims, judgments
and liabilities by or to third parties (plus litigation costs incurred) resulting from injury to or death of any person or physical
loss or damage to property arising out of defective materials, workmanship, or manufacture of the LGK® or the defective maintenance
of the LGK® (but, with respect to maintenance, only to the extent performed by or on behalf of Elekta).

7.3         End User shall defend and indemnify
Elekta and its Affiliates, agents, servants, and employees and hold them harmless from and against all damages, claims, judgments
and liabilities by or to third parties (plus litigation costs incurred) resulting from injury to or death of any person or physical
loss or damage to property arising out of the operation or medical use or misuse of the LGK® by or for End User (but which
is not attributable to defective materials, workmanship or manufacture of the LGK®), the defective maintenance of the LGK®
by or for End User (but only to the extent not performed by or on behalf of the Elekta), the failure of the Site to comply with
the Site Planning Criteria, or the training provided by Elekta.

 

ARTICLE VIII. MISCELLANEOUS
PROVISIONS.

 

8.1         Assignment. No party hereto
shall assign its respective rights or obligations under this Agreement (including the LGP Software License) in whole or in part
to any person without the prior written consent of the other party, except as provided in this Section 8.2 hereinafter. In the
event of any assignment or transfer by End User of its rights or duties under this Agreement or the Lease or of any sale, transfer,
lease or sublease of the LGK® or any component thereof to a third party, End User shall obtain the prior approval of Elekta
of the proposed transferee (such approval not to be unreasonably withheld) and cause such transferee, prior to such transfer, to
sign (1) an agreement that any acquired interest in the LGK® System is subject to the terms and conditions of this Agreement
and evidencing such transferee’s agreement to be bound, to the same extent as End User, by the then-surviving provisions
of this Agreement, including but not limited to the technical and scientific information provisions (Section 3.3), the confidentiality
provisions (Article IV), the provisions of Articles V and VII hereof, and the provisions of the LGK® Software License or (2)
a similar agreement otherwise approved by the Elekta, which approval shall not be unreasonably withheld.

8.2         Subcontractors. Elekta
shall be entitled to appoint subcontractors or any other third parties for the performance or fulfillment in whole or in part of
Elekta’s obligations under this Agreement without the consent of End User, and Elekta shall be fully responsible and liable
for the performance of other entities. Elekta shall be entitled to assign any of its rights or obligations hereunder to any of
its Affiliates without the consent of End User, but Elekta agrees that it will be fully responsible for any obligations assigned
to Elekta’s Affiliates hereunder.

8.3         Arbitration. All disputes
arising in connection with this Agreement shall be finally resolved by arbitration in Atlanta, Georgia under the Commercial Arbitration
Rules of the American Arbitration Association. Judgment upon the award rendered may be entered in any court having jurisdiction
or application may be made to such court for judicial acceptance of such award and an order of enforcement as the case may be.
The parties hereby agree the rendering of an award by the arbitrator or arbitrators shall be a condition precedent to the initiation
of any legal proceeding with respect to any dispute arising in connection with this Agreement. This Agreement shall be governed
by and construed in accordance with the laws of the State of Georgia and the United States.

8.4         Entire Agreement. This Agreement
constitutes the entire agreement between the parties hereto and supersedes any prior or contemporaneous agreements, negotiations
or discussions between the parties with respect to the subject matter hereof. No amendment of the provisions of this Agreement
will be valid unless made in writing and signed by both parties hereto..

 

IN WITNESS WHEREOF, the parties
hereto have signed this Agreement in duplicate as of the date first written above.

 

	ELEKTA INC.	 	END USER
	 	 	 
	By: 	/s/ Ian Dickson	 	By: 	/s/ Denise Schepici
	 	 	 	 	 
	Title:  	Treasurer	 	Title: 	Sr. Vice President
	 	 	 	 	 
	Date: 	11/6/13	 	Date: 	8/1/13

 

    	20

    	 

    

 

EXHIBIT A

SPECIFICATION

Leksell Gamma Knife ® PERFEXIONTM

	 

 

PRODUCT SPECIFICATION

 

Standard turn-key system

 

	Qty	 	Description	 	Article no.
	1	 	Leksell Gamma Knife® PERFEXIONTM	 	715000
	2	 	Leksell® Coordinate FrameTM Kit for PERFEXIONTM	 	1002407
	1	 	Leksell GammaPlan®	 	in BOM
	1	 	PERFEXIONTM system tool kit	 	 
	1	 	LSS Spare Part Kit for Leksell® Coordinate FrameTM	 	1002406
	1	 	Skull scaling instrument	 	A0202-01
	1	 	CT planning kit	 	 
	1	 	MRI planning kit	 	 
	1	 	X-ray planning kit	 	 
	1	 	Set of Co60 sources	 	2000000
	 	 	Cobalt loading	 	 
	 	 	Site planning	 	 
	 	 	Installation and commissioning	 	 
	1	 	Support and Education & Training for PERFEXIONTM	 	
        SER PERFEXION

        0001

	

 

    	21

    	 

    

Leksell Gamma Knife® PERFEXIONTM 

Radiation unit

- With radiation shielding doors and collimator system.

 

Patient Positioning SystemTM

- Patient couch and automatic Patient Positioning
System.

 

Covers for radiation unit and Patient Positioning
System

 

Electric cabinet

- Electric cabinet with cabling

- ECU - central unit and safety system electronic
board, circuit breakers and cabling.

- SDU - sector drive electronic board, circuit breakers
and cabling

- PPC1-software

- PPC2- software

- Medical UPS

 

Operator area

- Office cabinet

- Keyboard and mouse

- Operator console with patient and operator audio/video,
power supply, opto insulators, cabling and connectors

Flat screen monitors

Office UPS

 

MCU kit

MCU PC with USB CAN

MCU software

 

Treatment couch

Height adjustable mattress

Manual controls for treatment setup

 

Frame adapter

Model “Standard G”. For interfacing between
Leksell Coordinate Frame model G and Leksell Gamma Knife PERFEXIONTM.

 

Clearance check tool

 

Document set

Installation and supplementary documents

2 instructions for use

2 emergency routines

Signs and labels

 

    	22

    	 

    

 

Leksell® Coordinate Frame®
Kit for PERFEXIONTM 

 

Includes:

 

	Qty	Consists Of:	Article No.
	1	Frame with Feet and Straight Front Piece	50487-01
	1	Front Piece, Curved	60638-01
	2	Insulated Fixation Post, Anterior	912462
	2	Insulated Fixation Post, Short Posterior	912463
	2	Insulated Fixation Post, Long Posterior	912862
	6	Locking Screw, 5 x 19 mm, Titanium	60490-03
	6	Locking Piece for Fixation Post	60497-01
	1	Ear Plug Holder, Right	50498-01
	1	Ear Plug Holder, Left	50498-02
	2	Ear Plug	60136-01
	1	Fixation Screws, Titanium, kit of 20 pairs	907999
	2	Instrument Screw Driver, Double	50146-02
	1	Sterilizing Tray for Frame	50151-03
	4	Disposable Inserts, 25x4 pieces	912464
	1	Instruction for Use, Leksell® Coordinate Frame kit 003818	 
	1	Instructions for Use, Insulated Fixation Posts	012594
	1	Quick Reference Guide	014611

 

PERFEXIONTM system tool kit

Includes:

	QA tool	1001182

- For radiation focus precision check.

	Frame Cap	717960

- The frame cap is used during patient preparation
for a treatment with Leksell Gamma Knife® PERFEXIONTM.

 

LSS Spare Part Kit for Leksell®
Coordinate FrameTM Consists of 4 pieces of each of the following;

- Locking Screw, 5 x 19 mm, Titanium

- Locking Piece for Fixation Post

- Screw, 4 x 10 mm, Titanium

 

Skull scaling instrument

For measurement of skull shape for Leksell GammaPlan®
modeling

 

    	23

    	 

    

 

	CT planning kit	 
	Includes:	 
	CT indicator	A0800-11
	- Fiducial box for CT imaging procedure	 
	CT adapter	A0400-04
	- Fixating the stereotactic frame to the CT table fixation	 
	CT table fixation	A0401-XX
	- Fixating the CT adapter to specified CT table.	 
	 	 
	MRI planning kit	 
	Includes:	 
	MR adapter	A0420-XX
	- Fixating the stereotactic frame to specified MR table.	 
	MR indicator	A0820-07
	- Fiducial box for MR imaging procedure	 
	 	 
	X-ray planning kit	 
	Includes:	 
	X-ray indicator	A0860-04
	- Fiducial box for angiography imaging procedure	 
	X-ray adapter and support	A0440-XX
	- Fixating the stereotactic frame to specified angiography table.	 

 

Standard LGP for LGK PERFEXION

Includes one (1) Leksell GammaPlan® (LGP) license for creating new treatment plans for Leksell Gamma Knife®
PERFEXIONTM .This main license allows the addition, management and storage of an unlimited number patient records and treatment
plans. LGP also allows the visualization of treatment plans created at other LGK units.

 

    	24

    	 

    

 

Leksell GammaPlan® for
Leksell Gamma Knife® PERFEXIONTM includes:

 

1 STANDARD LGP FOR PERFEXION
LICENSE

 

Includes one (1) Leksell GammaPlan® (LGP) license
for creating new treatment plans for Leksell Gamma Knife® PERFEXIONTM .This main license allows the addition, management and
storage of an unlimited number patient records and treatment plans. LGP also allows the visualization of treatment plans created
at other LGK units.

 

1 RETREATMENTTM LICENSE

 

This software add-on facilitates planning of treatments
days before surgery, the assessment of treatments and re-treatments. Users are free to plan days ahead of treatment, to prepare
tomorrow’s follow-ups and plan additional treatment. Re-TreatmentTM also lets any user to integrate images and vital treatment
information from previous plans. It is a powerful tool to import and display previous key treatment data in the new treatment images.
Imported data are user defined regions (targets, risk structures) and prescription isodose. It increases the customer confidence
when treating new lesions after an initial treatment.

 

1 WARPSPEEDTM, REAL-TIME DOSE UPDATE LICENSE

 

This add-on speeds up planning by allowing the update
of isodoses instantly during planning. Isodoses displayed in any workspace are instantly updated whenever one or several isocenters
are added, modified, or removed. It is possible to fully apprehend the potential of composite shots, while also simplifying the
elaboration of new dose plans. WarpSpeedTM provides a shorter learning curve, more intuitive and faster planning.

 

1 FUNCTIONAL PLANNINGTM LICENSE

 

This software add-on allows users to perform some
functional procedures based on the definition on the AC-PC line the visualization of functional targets based on functional target
formulas.

 

1 IMAGEMERGETM LICENSE

 

This software add-on allows an automatic or manual
co-registration of any frameless image studies with a frame based reference study. Once co-registered, the frameless image can
be used in LGP like any other study. Supports MR, CT and PET images (requires the optional module ColorPETTM).

 

1 COLOR PETTM LICENSE

 

The ColorPETTM software add-on help users to can combine the physiological data of PET images with the anatomical
data of CT and MR images using predefined color lookup tables. Requires the ImageMerge software add-on.

 

    	25

    	 

    

 

Color Printer 110V

Network color laser printer with

-         Ethernet connector, minimum speed 10/100

-         Support for Postscript Level 3 printing

-         Power supply 110 V

-         English menus and labels

-         Support for printing A4, US letter, US executive
and US legal

Delivered model: HP Color Laser Jet or similar

 

Additional Training for Leksell Gamma Knife®
PERFEXIONTM

 

6               Clinical Training

Principle and practice of Gamma Knife Surgery, clinical
lectures, treatment planning, patient treatment - 5 days. Arranged by Elekta in collaboration with participating hospital.

 

1                LGP – DICOM RT License

DICOM RT provides an exclusive possibility to share
treatment information with any DICOM RT compatible system. It includes:

IMPORT of DICOM RT STRUCT allows
displaying any user-defined region/volume created on a DICOM RT system. Volumes can be target volumes, organ at risks, isodoses
or any other region of interest defined by the user.

EXPORT of treatment data via DICOM RT STRUCT and DICOM RT DOSE allows sharing information with any compatible
systems to perform dose comparison or dose addition.

 

    	26

    	 

    

 

Technical Specifications

 

	Workflow
	Automatic positioning system	Couch integrated
	Typical repositioning time	< 3 s
	Typical collimator size setup time	< 3 s
	Blocked collimation setup time	< 3 s
	Mixed collimation setup time (Composite shot)	< 3 s
	Check and verify	100%
	QA procedure	Automatic
	Accuracy
	Radiological accuracy	< 0.5 mm
	 	 
	Positioning repeatability	< 0.05 mm
	Maximum patient weight	210 kg (460 pounds)
	Treatment planning
	Treatment planning system	PC/Linux based
	Dynamic shaping	Yes
	Remote planning	Yes
	Image co-registration	Yes
	PET supported	Yes
	Mechanical treatment range X/Y/Z	160/180/220 mm
	Shape of accessible volume	Cylindrical
	Real collimator sizes	4,8,16 mm diameter
	Radiation data
	Total cobalt-60 activity at loading (approx.)	< 6,600 Curie (2.44 x 1014 Bq)
	Number of radiation sources	192
	Radiation dose rate at focal point at loading	> 3 Gy/min
	Physical data
	Overall length, including cover	4.46 m
	Overall width, including cover	2.12 m
	Overall height, including cover	1.91 m
	Total weight (approximate)	20,000 kg

 

    	27

    	 

    

 

Radiation
unit

 

The radiation unit is the radiation delivery system. It houses
192 Cobalt-60 sources and the collimator system that directs the radiation to the focus point. The radiation unit incorporates
the management of the shielding doors and electro-mechanics of the source sectors.

 

The following section describes selected components within the
radiation unit.

 

All components are chosen from well-recognized suppliers to
secure reliability and to optimize performance of the system.

 

	Collimator body with radiation shielding
	Collimator body	Tungsten body with 576 collimator channels.
	Collimators	Tungsten collimator inserts.
	Pre-collimator	576 lead pre-collimator channels.
	Outer shielding	Cast iron.
	Inner shielding	Tungsten and lead.
	Bearing for collimator body	Crossed roller bearing. Static axial load 680000 N
	Shielding doors	Steel.
	Shielding strips	Stainless Steel.
	Servo Controller	High precision, fully digital servo drive with embedded intelligence.
	Motor	DC motor with 2000 line encoder
	Linear guide	 
	Linear guide blocks	Caged ball technology.
	Gear	Planetary gear
	Clutch	Ratchetting clutch
	8 source carrying sector units
	Sector	Aluminum. 24 source housing
	Shafts	Induction hardened stainless steel.
	Bearings	Graphite bushings
	Motor	24V DC motor
	Encoder	500 impulses/turn
	Linear guide unit	Repeatability: ±0.003mm.
	Linear encoder	Absolute Linear encoder.
	Solenoid	Photo-micro sensor.
	Servo controllers	Intelligent servo card

 

    	28

    	 

    

 

Patient Positioning System

 

The Patient Positioning System is the component of the PERFEXIONTM
system that the patient reclines on for treatment and is positioned relative the point of focus in the radiation unit.

 

The following section describes selected components within the
Patient Positioning System.

 

All components are chosen from well-recognized suppliers to
secure reliability and to optimize the performance of Leksell Gamma Knife PERFEXION.

 

	Couch framework with X/Y/Z drive
	Framework	20 mm zinc chromated steel
	Motors	DC motors with 2000 line encoders.
	Gear	X/Y-axis Planetary gear 30:1 Z-axis Planetary gear 4:1
	Ball screws Bearing houses Support bearings	X/Z -axis.
	Screw jack	Y-axis: Integrated safety nut.
	Linear guides	 
	Linear guide blocks	Caged ball technology.
	Solenoid	Y-axis: Photo-micro sensor.
	Linear encoders	Absolute Linear encoders. Accuracy grade +/- 0.005mm.
	Servo Controllers	High precision, fully digital servo drive, with embedded intelligence.
	Frame fixation	Hardened stainless steel
	Comfort system
	Mattress support	Sandwich structure with aluminum honeycomb core and steel sheets
	Actuator	DC actuator
	Ball bearing	Stainless steel.
	Covers
	Radiation unit and couch covers	3 layers glass reinforced polyester. Meets ASTM E84 with flame spread index less than 75. Flammability rating V-0 according to UL 94.

 

    	29

    	 

    

 

Control System 

 

Office Cabinet

 

Includes:

 

MCU - Main Computer Unit

Office UPS - Uninterrupted Power Supply 

Ethernet Switch

 

Operators Console

Includes:

 

CIU - Connection and Isolation Unit

The CIU is powered by the office UPS and the internal power
supply converting 100-250VAC to 24VDC.

 

PSS - Patient Surveillance system

The PSS is included in the operator console as a separate unit
and handles the video/audio signals of the PERFEXIONTM system. It is possible to connect a video recorder on the ‘auxiliary’
outputs.

External audio system, e.g., patients MP3 player, can be connected
and played over the sound system integrated in the radiation unit covers.

 

MCU Monitor

19” Flat screen, UL-approved.

The MCU Monitor shows the Graphical User Interface of the MCU.

 

PSS Monitor

19” Flat screen, UL-approved.

The PSS monitor shows the video from the patient camera and
provides the sound from the patient microphone.

 

Treatment room Monitor

19” Flat screen, UL-approved.

The treatment room monitor displays the same information as
the MCU monitor on the operators console.

 

Treatment room Camera

The treatment room camera provides video to the PSS Monitor
in the Operators Area.

 

Medical Cabinet

Includes:

 

SDU - Sector Drive Unit

The SDU contains 8 servo controllers (one for each sector).

 

ECU - Electronic Control Unit

The Control Unit consists of two complete Power PCs (PPC) with
peripherals (RAM, ROM, inputs, outputs, CAN interfaces).

 

Medical UPS - Uninterrupted Power Supply

The medical UPS delivers 24VDC and 48VDC needed for the PERFEXIONTM
system. It is approved for medical use.

 

Radiation phantom

The
Radiation Phantom with Cassettes is used for calibrating the absorbed dose rate of Leksell Gamma Knife®.

 

    	30

    	 

    

 

INFORMATION TO BE FURNISHED BY BUYER

 

Not later than six months prior to the Contractual Delivery
Date or two weeks after the Effective Date, whichever occurs later, Buyer shall inform Seller in writing of:

 

(i)      the orientation of the LGK

 

(ii)     the minimum lengths of cables required to connect the
LGK at the Site; and

 

(iii)    the manufacturer and model numbers of the CT, MRI and angiographic equipment which
Buyer intends to use in connection with the LGK.

 

    	31

    	 

    

 

EXHIBIT B

DESCRIPTION OF SITE

 

TUFTS MEDICAL CENTER

750 WASHINGTON ST STE 1012

BOSTON, MA 02111-1526

 

    	32

    	 

    

 

EXHIBIT C

ELEKTA'S WARRANTY

 

		1.	Subject to the exceptions set forth below, Elekta warrants to Buyer
that for one year from the date of completed Installation Test Protocol, the LGK will perform consistently with the Specification
and the LGK will be free from defects in design, materials, and workmanship which result in non-compliance with the Specification,
except as otherwise provided herein below. Notwithstanding the foregoing, Elekta’s warranty set forth in this Section 1 does
not cover:

 

		(i)	defects arising out of materials or parts provided, modified or designed by Buyer;

(ii)         defects emanating from Buyer’s improper
use or maintenance;

(iii)         normal deterioration or normal wear and tear,
including radioactive decay of the Cobalt Supply;

		(iv)	defects resulting from repairs or service of the LGK supplied other than by Elekta or its authorized representative;

		(v)	defects in the Hardware (and its operating software) (the warranty for which is regulated in Section 7 below) or the LGP Software
(the warranty for which is regulated in Section 2 below).

		(vi)	the training referred to in Subsection 3.2 of the Terms and Conditions; or

		(vii)	defects in positioning or in the Site.

 

		2.	Elekta warrants that the LGP Software will, for a period of one year from the date of the completed Installation Test Protocol,
perform substantially in accordance with the documentation delivered with such LGP Software. The warranty set forth in this Section
2 shall not apply if the LGP Software is subject to unauthorized repair or modification, improper application, improper installation,
accidental damage, negligence in use, improper storage, acts of God, electrical power damage, equipment malfunction, or abnormal
operating conditions, and in the event of any of the foregoing, Buyer shall be responsible to pay Elekta’s then standard
charges for any repairs, replacements or services performed by Elekta.

 

		3.	In the event that the LGK or any part or component thereof shall fail to conform with the relevant warranty described herein,
Elekta shall (or cause one of its Affiliates to) promptly repair or replace, at its option and at its expense, the defect in the
LGK or component thereof. Repair or replacement parts furnished or work performed under this warranty shall be warranted for a
period of one year from and after the date of such repair of replacement, but in no event shall any such warranty with respect
to repair or replacement work or parts extend past that date which is two (2) years from and after the date of completion of the
Installation Test Protocol. The defective LGK or part thereof which is replaced in accordance with this warranty shall be the property
of Elekta, and Elekta will notify Buyer in writing immediately after repair or replacement as to what disposition Elekta desires
of such LGK or part thereof, all at Elekta’s cost.

 

		4.	In order to avail itself of its rights under this warranty,
Buyer shall immediately notify Elekta in writing of any defects that appear under the warranty and shall give Elekta every opportunity
of inspecting and remedying such defects.

 

		5.	Year 2000 Compliance Warranty. Elekta further warrants
that the equipment, software and use of data will be year 2000 compliant and accommodate a full year calculation in its software.
Licensor will guarantee that the equipment and software will accept all data and perform to comply with the year 2000 warranties,
assuring that the full four (4) positions (e.g. 1997) year is utilized.

 

		6.	THE FOREGOING WARRANTIES ARE EXCLUSIVE AND GIVEN AND
ACCEPTED IN LIEU OF ALL OTHER WARRANTIES OF ELEKTA OR ITS REPRESENTATIVES WITH RESPECT TO QUALITY, PERFORMANCE AND OPERATION OF
THE LGK, WRITTEN OR ORAL, EXPRESSED OR IMPLIED. ALL OTHER WARRANTIES OF ELEKTA OR ITS REPRESENTATIVES, INCLUDING, WITHOUT LIMITATION,
ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE ARE HEREBY EXPRESSLY DISCLAIMED. CORRECTION OF NON-CONFORMITIES
OR DEFECTS AS PROVIDED ABOVE SHALL BE BUYER’S EXCLUSIVE REMEDY AND SHALL CONSTITUTE FULL AND FINAL FULFILLMENT OF ALL LIABILITIES
OF ELEKTA, WHETHER IN WARRANTY, CONTRACT, NEGLIGENCE, STRICT LIABILITY, TORT OR OTHERWISE WITH RESPECT TO THE LGK. IN NO EVENT
SHALL ELEKTA BE LIABLE FOR LOSS OF USE, REVENUE OR PROFIT, OR FOR ANY OTHER DIRECT, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGE
ARISING IN ANY RESPECT FROM THE LGK OR ITS USE, OPERATION OR PERFORMANCE. THE PROVISIONS OF THIS PARAGRAPH SHALL SURVIVE THE TERMINATION
OF THIS AGREEMENT.

 

		 7.	Elekta shall assign to Buyer all of Elekta’s rights under the
warranty or warranties provided by the manufacturer (the “Computer Manufacturer”) for the Hardware and operating software
included in the LGK. In the event the Hardware or operating software exhibit defects which are covered by the warranty of the Computer
Manufacturer, Buyer may notify Elekta of the nature of such defects. In such case, Elekta shall promptly inform the Computer Manufacturer
thereof and use its best efforts to arrange prompt repair service by the Computer Manufacturer pursuant to the terms of the Computer
Manufacturer’s warranty or warranties Elekta shall furnish Buyer with such reasonable cooperation as Buyer may request with
respect to the purchase by Buyer of any extended warranty or maintenance contract offered by the Computer Manufacturer.

 

    	33

    	 

    

 

EXHIBIT D

LEKSELL GAMMAPLAN® PFXTM
SOFTWARE LICENSE

 

		1.	LGP Software

		1.1	Elekta hereby licenses to Buyer at no additional cost beyond the Purchase Price, the LGP Software, to be utilized only for
the purpose of planning dosages of treatments to be performed with the LGK. In case Buyer already has an existing Leksell Gamma
Knife® Buyer may also retain one license to the old Leksell Gamma Plan® software for archival purposes.
Such license is also subject to the license terms and conditions set out in this Exhibit E. Such license is for the use by Buyer
of the software at one (1) workstation.

		1.2	Buyer shall not: (a) use LGP except in connection with the radiosurgical operations performed with the LGK at the Site; (b)
make any modification to, adapt, translate, decompile, disassemble or create derivative works based on LGP or merge LGP into any
other software; (c) reproduce LGP (or any portion thereof) or any materials related thereto except for one back-up copy made as
part of Buyer’s regular computer software maintenance routines; (d) transfer, assign or sublicense LGP to any person except
to an assignee of all of Buyer’s rights in this Agreement in a manner permitted by Section 8.1 of the Terms and Conditions;
or (e) use LGP in connection with any access terminal other than the Hardware which has been specifically approved by Elekta in
writing.

		1.3	All right, title, interest and ownership of, in and to LGP, including but not limited to all trademarks, service marks, registrations,
copyrights, and all other proprietary rights not expressly granted in this License, shall at all times remain the exclusive property
of Elekta. Elekta shall retain all rights to LGP recorded on the original disk(s) and all subsequent copies of LGP, in whatever
form recorded.

		1.4	The term of Buyer’s license to LGP shall continue until the earlier of: (a) any sublicense, assignment or transfer or
attempted sublicense, assignment or transfer by Buyer of LGP without the consent of Elekta; (b) the transport, movement or attempted
transport or movement by the Buyer of LGP, or the Hardware on which LGP is installed, from the Site without prior written consent
of Elekta; (c) any modification or adaptation of LGP for use with any equipment other than the LGK; (d) the use of LGP in connection
with more than one access terminal unless Buyer has obtained the written consent of Elekta to the use of more than one access terminal
at the same time or in connection with any access terminal other than the Hardware which has not been specifically approved by
Elekta in writing; or (E) the mutual written consent of Buyer and Elekta.

 

		2.	Buyer’s Responsibilities Concerning Hardware and
LGP

		2.1	To facilitate E-Mail/Internet support, Buyer shall provide for E-Mail/Internet connectivity.

		2.2	Buyer shall assign a system manager who will undergo the appropriate training on the operating system HP-UX and /or already
have sufficient UNIX system administrator experience. Such training will be provided by the Hardware manufacturer and Elekta shall
pay the fee therefore. Buyer shall pay all travel and other expenses associated with such training.

		2.3	If Buyer elects to transfer images by a data network, then :

		(a)	Buyer shall provide the format to and right to read the diagnostic images generated by the user’s
diagnostic equipment and planned to be used as input for LGP. The Buyer shall provide a sample image in digital and hard copy form
in the orientation intended for clinical use.

		(b)	Buyer is responsible for obtaining up-to-date and accurate scanner image formats and any other
scanner or PACS information from vendors necessary to integrate images into LGP and providing this to Elekta.

		(c)	The Hardware used to run LGP must be used solely for this purpose. All changes and additions to
LGP and/or Hardware running LGP must receive prior written approval of Elekta.

		(d)	Buyer shall provide the images via an Ethernet connection using TCP/IP protocol and will provide
all physical cabling to the LGP Hardware compatible with 100-Base-T or 1000-Base-T at the Installation location of the LGK.

		(e)	Buyer shall provide all TCP/IP networking parameters such as IP address, netmask, gateway address,
etc. for the HP workstation included as a part of the Hardware.

 

    	34

    	 

    

 

EXHIBIT E

 

END USER AGREEMENT AMENDMENTS

 

This
page left intentionally blank.

 

    	35

    	 

    

 

Exhibit 2

 

PER PROCEDURE PAYMENTS

  

	
         

        Annual Procedures Performed
	 	
        Initial Non-Medicare

        Fee Per Procedure
	 	
        Initial Medicare

        Fee Per Procedure1

	* 	 	*	 	*
	*	 	*	 	*
	*	 	*	 	*
	*	 	*	 	*

 

Notwithstanding anything to the contrary
set forth herein, (a) for purposes of determining the per procedure payment, the number of annual procedures performed shall be
reset to zero (0) on each anniversary of the first day of the first full month after the Effective Date of this Agreement; (b)
for purposes of determining the applicable per procedure payment tier, non-Medicare and Medicare procedures will be grouped chronologically
as they are performed; and (c) there shall be no retroactive adjustment of the per procedure payment irrespective of whether the
number of procedures performed during any fiscal year reaches a lower per procedure payment level. For example, if during an annual
measuring period, * procedures are performed (of which * are non-Medicare procedures and * are Medicare procedures), then, (i)
for each of the first * procedures performed (irrespective of the number of non-Medicare and Medicare procedures comprising the
first * procedures), Medical Center would pay * for each non-Medicare procedure and * for each Medicare procedure; and (ii) for
each of the next * procedures performed (irrespective of the number of non-Medicare and Medicare procedures comprising the next
* procedures), Medical Center would pay * for each non-Medicare procedure and * for each Medicare procedure.

 

    	36

    	 

    

 

Exhibit 3

 

DESIGNATED PAYORS

 

 

*

 

*

 

*

 

*

 

*

 

    	37THE REGISTERED HOLDER
OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT
AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR
HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGHTY DAYS FOLLOWING THE EFFECTIVE DATE (DEFINED BELOW) TO ANYONE
OTHER THAN (I) AEGIS CAPITAL CORP. OR AN UNDERWRITER OR A SELECTED DEALER IN CONNECTION WITH THE OFFERING, OR (II) A BONA FIDE
OFFICER OR PARTNER OF AEGIS CAPITAL CORP. OR OF ANY SUCH UNDERWRITER OR SELECTED DEALER.

 

THIS WARRANT AND THE
SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR ANY OTHER SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE
OF (1) AN EFFECTIVE REGISTRATION STATEMENT COVERING SUCH SECURITIES UNDER THE SECURITIES ACT AND ANY OTHER APPLICABLE SECURITIES
LAWS, OR (2) AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO COLLABRX, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.

 

THIS PURCHASE WARRANT
IS NOT EXERCISABLE PRIOR TO [________________] [DATE THAT IS ONE YEAR FROM THE DATE OF CLOSING]. VOID AFTER 5:00 P.M., EASTERN
TIME, [___________________] [DATE THAT IS FIVE YEARS FROM THE DATE OF CLOSING].

  

 

COMMON STOCK PURCHASE WARRANT

 

 

For the Purchase of [_____] Shares of Common
Stock

 

of

 

CollabRx, Inc.

  

1.          Purchase
Warrant. THIS CERTIFIES THAT, in consideration of the payment of $100.00 and for other good and value consideration paid by
or on behalf of Aegis Capital Corp. or its assigns (“Holder”), as registered
owner of this Purchase Warrant, to CollabRx, Inc., a Delaware corporation (the “Company”), Holder is entitled,
at any time or from time to time from [________________] [DATE THAT IS ONE YEAR FROM THE DATE OF CLOSING] (the “Commencement
Date”), and until at or before 5:00p.m., Eastern time, [____________] [DATE THAT IS FIVE YEARS FROM CLOSING]
(the ”Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up
to [____] shares of common stock of the Company, par value $0.01 per share (the “Shares”), subject to adjustment
as provided in Section 6 hereof. If the Expiration Date is a day on which banking institutions are authorized by law to close,
then this Purchase Warrant may be exercised on the next succeeding day which is not such a day in accordance with the terms herein.
During the period ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant.
This Purchase Warrant is initially exercisable at $[___] per Share [125% of the price of the Shares sold in the Offering];
provided, however, that upon the occurrence of any of the events specified in Section 6 hereof, the rights granted
by this Purchase Warrant, including the exercise price per Share and the number of Shares to be received upon such exercise, shall
be adjusted as therein specified. The term “Exercise Price” shall mean the initial exercise price or the adjusted
exercise price, depending on the context. 

 

    	1

    	 

    

 

2.          Exercise.

 

2.1          Exercise
Form. In order to exercise this Purchase Warrant, the exercise form attached hereto must be duly executed and completed and
delivered to the Company, together with this Purchase Warrant and payment of the Exercise Price for the Shares being purchased
payable in cash by wire transfer of immediately available funds to an account designated by the Company or by certified check or
official bank check. If the subscription rights represented hereby shall not be exercised at or before 5:00 p.m., Eastern time,
on the Expiration Date, this Purchase Warrant shall become and be void without further force or effect, and all rights represented
hereby shall cease and expire.

 

2.2          Cashless
Exercise. If at any time after the Commencement Date there is no effective registration statement registering, or no current
prospectus available for, the resale of the Shares by the Holder, then in lieu of exercising this Purchase Warrant by payment of
cash or check payable to the order of the Company pursuant to Section 2.1 above, Holder may elect to receive the number of Shares
equal to the value of this Purchase Warrant (or the portion thereof being exercised), by surrender of this Purchase Warrant to
the Company, together with the exercise form attached hereto, in which event the Company shall issue to Holder, Shares in accordance
with the following formula:

 

	X	=	Y(A-B)	 
	A	 

 

	Where,	 	 	 
	 	X	=	The number of Shares to be issued to Holder;
	 	Y	=	The number of Shares for which the Purchase Warrant is being exercised;
	 	A	=	The fair market value of one Share; and
	 	B	=	The Exercise Price.

 

For purposes of this
Section 2.2, the fair market value of a Share is defined as follows:

 

		(i)	if the Company’s common stock is traded on a securities
exchange, the value shall be deemed to be the average of the closing prices on such exchange over each of the two (2) trading
days prior to the date exercise form is submitted in connection with the exercise of the Purchase Warrant; or

                 

		(ii)	if the Company’s common stock is actively traded
over-the-counter, the value shall be deemed to be the average of the closing bid prices over each of the two (2) trading days
prior to the date the exercise form is submitted in connection with the exercise of the Purchase Warrant; if there is no active
public market, the value shall be the fair market value thereof, as determined in good faith by the Company’s Board of Directors.

 

    	2

    	 

    

 

2.3          Legend.
Each certificate representing Shares shall bear a legend as follows unless such securities have been registered under the Securities
Act of 1933, as amended (the “Securities Act”):

 

“The securities
represented by this certificate have not been registered under the Securities Act of 1933, as amended (the “Act”),
or applicable state law. Neither the securities nor any interest therein may be offered for sale, sold or otherwise transferred
except pursuant to an effective registration statement under the Securities Act, or pursuant to an exemption from registration
under the Securities Act and applicable state law which, in the opinion of counsel to the Company, is available.”

 

3.          Transfer.

 

3.1          General Restrictions
on Transfer of Purchase Warrant. The Holder of this Purchase Warrant agrees by his, her or its acceptance hereof, that such
Holder will not: (a) sell, transfer, assign, pledge or hypothecate this Purchase Warrant for a period of one hundred eighty (180)
days following the Effective Date to anyone other than: (i) Aegis Capital Corp. (“Aegis”) or an underwriter
or a selected dealer participating in the offering, or (ii) a bona fide officer or partner of Aegis or of any such underwriter
or selected dealer, in each case in accordance with FINRA Conduct Rule 5110(g)(1), or (b) cause this Purchase Warrant or the Shares
to be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition
of this Purchase Warrant or the Shares, except as provided for in FINRA Rule 5110(g)(2). On and after 180 days after the Effective
Date, transfers of this Purchase Warrant to others may be made subject to compliance with or exemptions from applicable securities
laws. In order to make any permitted assignment of this Purchase Warrant, the Holder must deliver to the Company the assignment
form attached hereto duly executed and completed, together with the Purchase Warrant and payment of all transfer taxes, if any,
payable in connection therewith. Upon receipt by the Company of the duly executed and completed assignment form, the Purchase Warrant
and all required transfer taxes, the Company shall within five (5) business days thereafter transfer this Purchase Warrant on the
books of the Company and shall execute and deliver a new Purchase Warrant or Purchase Warrants of like tenor to the appropriate
assignee(s) expressly evidencing the right to purchase the aggregate number of Shares purchasable hereunder or such portion of
such number as shall be contemplated by any such assignment.

 

3.2          Restrictions
Imposed by the Securities Act. The Holder shall not be transfer the Shares unless and until: (i) the Company has received the
opinion of counsel for the Holder that the Shares may be transferred pursuant to an exemption from registration under the Securities
Act and applicable state securities laws, the availability of which is established to the reasonable satisfaction of the Company
(the Company hereby agreeing that the opinion of Sichenzia Ross Friedman Ference LLP shall be deemed satisfactory evidence of the
availability of an exemption), or (ii) a registration statement or a post-effective amendment to the Registration Statement relating
to the offer and sale of the Shares has been filed by the Company and declared effective by the U.S. Securities and Exchange Commission
(the ”Commission”) and compliance with applicable state securities law has been established.

 

    	3

    	 

    

 

4.          Registration Rights.

 

4.1          Demand Registration.

 

4.1.1          Grant of
Right. The Company, upon written demand (a “Demand Notice”) of the Holder(s) of at least 51% of the Purchase
Warrants and/or the underlying Shares (“Majority Holders”), agrees to register, on one occasion, all or any portion
of the Shares underlying the Purchase Warrants (collectively, the “Registrable Securities”). On such occasion,
the Company will file a registration statement with the Commission covering the Registrable Securities within sixty (60) days after
receipt of a Demand Notice and use its reasonable best efforts to have the registration statement declared effective promptly thereafter,
subject to compliance with review by the Commission; provided, however, that the Company shall not be required to
comply with a Demand Notice if the Company has filed a registration statement with respect to which the Holder is entitled to piggyback
registration rights pursuant to Section 4.2 hereof and either: (i) the Holder has elected to participate in the offering covered
by such registration statement or (ii) if such registration statement relates to an underwritten primary offering of securities
of the Company, until the offering covered by such registration statement has been withdrawn or until thirty (30) days after such
offering is consummated. The demand for registration may be made at any time during a period of four (4) years beginning on the
Commencement Date. The Company covenants and agrees to give written notice of its receipt of any Demand Notice by any Holder(s)
to all other registered Holders of the Purchase Warrants and/or the Registrable Securities within ten (10) days after the date
of the receipt of any such Demand Notice.

 

4.1.2          Terms.
The Company shall bear all fees and expenses attendant to the registration of the Registrable Securities pursuant to Section 4.1.1,
but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to
represent them in connection with the sale of the Registrable Securities. The Company agrees to use its reasonable best efforts
to cause the filing required herein to become effective promptly and to qualify or register the Registrable Securities in such
states as are reasonably requested by the Holder(s); provided, however, that in no event shall the Company be required
to register the Registrable Securities in a state in which such registration would cause: (i) the Company to be obligated to register
or license to do business in such state or submit to general service of process in such state, or (ii) the principal shareholders
of the Company to be obligated to escrow their shares of capital stock of the Company. The Company shall use its reasonable best
efforts to cause any registration statement filed pursuant to the demand right granted under Section 4.1.1 to remain effective
for a period of at least twelve (12) consecutive months after the date that the Holders of the Registrable Securities covered by
such registration statement are first given the opportunity to sell all of such securities. The Holders shall only use the prospectuses
provided by the Company to sell the shares covered by such registration statement, and will immediately cease to use any prospectus
furnished by the Company if the Company advises the Holder that such prospectus may no longer be used due to a material misstatement
or omission. Notwithstanding the provisions of Section 4.1, the Holder shall be entitled to a demand registration under this Section
4.1.2 on only one (1) occasion and such demand registration right shall terminate on the fifth anniversary of the Effective Date
in accordance with FINRA Rule 5110(f)(2)(H)(iv).

 

    	4

    	 

    

 

4.2          “Piggy-Back”
Registration.

 

4.2.1          Grant of
Right. In addition to the demand right of registration described in Section 4.1 hereof, the Holder shall have the right, to
include the Registrable Securities as part of any other registration of securities filed by the Company (other than in connection
with a transaction contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8 or any equivalent form);
provided, however, that if, solely in connection with any primary underwritten public offering for the account of
the Company, the managing underwriter(s) thereof shall, in its reasonable discretion, impose a limitation on the number of shares
of common stock which may be included in the Registration Statement because, in such underwriter(s)’ judgment, marketing
or other factors dictate such limitation is necessary to facilitate public distribution, then the Company shall be obligated to
include in such Registration Statement only such limited portion of the Registrable Securities with respect to which the Holder
requested inclusion hereunder as the underwriter shall reasonably permit. Any exclusion of Registrable Securities shall be made
pro rata among the Holders seeking to include Registrable Securities in proportion to the number of Registrable Securities sought
to be included by such Holders; provided, however, that the Company shall not exclude any Registrable Securities
unless the Company has first excluded all outstanding securities, the holders of which are not entitled to inclusion of such securities
in such Registration Statement or are not entitled to pro rata inclusion with the Registrable Securities.

 

4.2.2          Terms.
The Company shall bear all fees and expenses attendant to registering the Registrable Securities pursuant to Section 4.2.1 hereof,
but the Holders shall pay any and all underwriting commissions and the expenses of any legal counsel selected by the Holders to
represent them in connection with the sale of the Registrable Securities. In the event of such a proposed registration, the Company
shall furnish the then Holders of outstanding Registrable Securities with not less than thirty (30) days written notice prior to
the proposed date of filing of such registration statement. Such notice to the Holders shall continue to be given for each registration
statement filed by the Company until such time as all of the Registrable Securities have been sold by the Holder. The holders of
the Registrable Securities shall exercise the “piggy-back” rights provided for herein by giving written notice within
ten (10) days of the receipt of the Company’s notice of its intention to file a registration statement. Except as otherwise
provided in this Purchase Warrant, there shall be no limit on the number of times the Holder may request registration under this
Section 4.2.2; provided, however, that such “piggy-back” registration rights shall terminate on the seventh
anniversary of the Effective Date in accordance with FINRA Rule 5110(f)(2)(H)(v).

 

4.3          General Terms.

 

4.3.1          Indemnification.
The Company shall indemnify the Holder(s) of the Registrable Securities to be sold pursuant to any registration statement hereunder
and each person, if any, who controls such Holders within the meaning of Section 15 of the Securities Act or Section 20 (a) of
the Securities Exchange Act of 1934, as amended (“Exchange Act”), against all loss, claim, damage, expense or
liability (including all reasonable attorneys’ fees and other expenses reasonably incurred in investigating, preparing or
defending against any claim whatsoever) to which any of them may become subject under the Securities Act, the Exchange Act or otherwise,
arising from such registration statement but only to the same extent and with the same effect as the provisions pursuant to which
the Company has agreed to indemnify the Underwriter under Section 5.1 of the Underwriting Agreement between Aegis and the Company,
dated as of [___________] (the “Underwriting Agreement”). The Holder(s) of the Registrable Securities to be
sold pursuant to such registration statement, and their successors and assigns, shall severally, and not jointly, indemnify the
Company, its directors, its officers who signed the registration statement and persons who control the Company within the meaning
of Section 15 of the Securities Act or Section 20 of the Exchange Act against all loss, claim, damage, expense or liability (including
all reasonable attorneys’ fees and other expenses reasonably incurred in investigating, preparing or defending against any
claim whatsoever) to which they may become subject under the Securities Act, the Exchange Act or otherwise, arising from information
furnished by or on behalf of such Holders, or their successors or assigns, in writing, for specific inclusion in such registration
statement to the same extent and with the same effect as the provisions contained in Section 5.2 of the Underwriting Agreement
pursuant to which the Underwriter has agreed to indemnify the Company and such persons.

 

    	5

    	 

    

 

4.3.2          Exercise
of Purchase Warrants. Nothing contained in this Purchase Warrant shall be construed as requiring the Holder(s) to exercise
their Purchase Warrants prior to or after the initial filing of any registration statement or the effectiveness thereof.

 

4.3.3          Documents
Delivered to Holders. The Company shall furnish to each Holder participating in any of the foregoing underwritten offerings
and to each underwriter of any such underwritten offering, if any, a signed counterpart, addressed to such Holder or underwriter,
of: (i) an opinion of counsel to the Company, dated the effective date of such registration statement (and, if such registration
includes an underwritten public offering, an opinion dated the date of the closing under any underwriting agreement related thereto),
and (ii) a “cold comfort” letter dated the effective date of such registration statement (and, if such registration
includes an underwritten public offering, a letter dated the date of the closing under the underwriting agreement) signed by the
independent registered public accounting firm which has issued a report on the Company’s financial statements included in
such registration statement, in each case covering substantially the same matters with respect to such registration statement (and
the prospectus included therein) and, in the case of such accountants’ letter, with respect to events subsequent to the date
of such financial statements, as are customarily covered in opinions of issuer’s counsel and in accountants’ letters
delivered to underwriter in underwritten public offerings of securities. The Company shall also deliver promptly to each Holder
participating in the offering requesting the correspondence and memoranda described below and to the managing underwriter, if any,
copies of all correspondence between the Commission and the Company, its counsel or auditors and all memoranda relating to discussions
with the Commission or its staff with respect to the registration statement and permit each Holder and underwriter to do such investigation,
upon reasonable advance notice, with respect to information contained in or omitted from the registration statement as it deems
reasonably necessary to comply with applicable securities laws or rules of FINRA. Such investigation shall include access to books,
records and properties and opportunities to discuss the business of the Company with its officers and independent auditors, all
to such reasonable extent and at such reasonable times as any such Holder shall reasonably request.

 

4.3.4          Underwriting
Agreement. The Company shall enter into an underwriting agreement with the managing underwriter(s), if any, selected by any
Holders whose Registrable Securities are being registered pursuant to this Section 4, which managing underwriter(s) shall be reasonably
satisfactory to the Company. Such agreement shall be reasonably satisfactory in form and substance to the Company, Aegis and such
managing underwriter(s), and shall contain such representations, warranties and covenants by the Company and such other terms as
are customarily contained in agreements of that type used by the managing underwriter(s). The Holders shall be parties to any underwriting
agreement relating to an underwritten sale of their Registrable Securities and may, at their option, require that any or all the
representations, warranties and covenants of the Company to or for the benefit of such underwriters shall also be made to and for
the benefit of such Holders. Such Holders shall not be required to make any representations or warranties to or agreements with
the Company or the underwriters except as they may relate to such Holders, their Shares and their intended methods of distribution.

 

    	6

    	 

    

 

4.3.5          Documents
to be Delivered by Holder(s). Each of the Holder(s) participating in any of the foregoing offerings shall furnish to the Company
a completed and executed questionnaire provided by the Company requesting information customarily sought of selling security holders.

 

4.3.6          Damages.
Should the registration or the effectiveness thereof required by Sections 4.1 and 4.2 hereof be delayed by the Company or the Company
otherwise fails to comply with such provisions, the Holder(s) shall, in addition to any other legal or other relief available to
the Holder(s), be entitled to obtain specific performance or other equitable (including injunctive) relief against the threatened
breach of such provisions or the continuation of any such breach, without the necessity of proving actual damages and without the
necessity of posting bond or other security.

 

5.          New Purchase Warrants to be Issued.

 

5.1          Partial Exercise
or Transfer. Subject to the restrictions in Section 3 hereof, this Purchase Warrant may be exercised or assigned in whole or
in part. In the event of the exercise or assignment hereof in part only, upon surrender of this Purchase Warrant for cancellation,
together with the duly executed exercise or assignment form and funds sufficient to pay any Exercise Price and/or transfer tax
if exercised pursuant to Section 2.1 hereto, the Company shall cause to be delivered to the Holder without charge a new Purchase
Warrant of like tenor to this Purchase Warrant in the name of the Holder evidencing the right of the Holder to purchase the number
of Shares purchasable hereunder as to which this Purchase Warrant has not been exercised or assigned.

 

5.2          Lost Certificate.
Upon receipt by the Company of evidence satisfactory to it of the loss, theft, destruction or mutilation of this Purchase Warrant
and of reasonably satisfactory indemnification or the posting of a bond, the Company shall execute and deliver a new Purchase Warrant
of like tenor and date. Any such new Purchase Warrant executed and delivered as a result of such loss, theft, mutilation or destruction
shall constitute a substitute contractual obligation on the part of the Company.

 

6.          Adjustments.

 

6.1          Adjustments
to Exercise Price and Number of Securities. The Exercise Price and the number of Shares underlying the Purchase Warrant shall
be subject to adjustment from time to time as hereinafter set forth:

 

6.1.1          Share Dividends;
Split Ups. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding shares
of the Company’s common stock is increased by a stock dividend payable in shares of the Company’s common stock or by
a split up of shares of the Company’s common stock or other similar event, then, on the effective day thereof, the number
of Shares purchasable hereunder shall be increased in proportion to such increase in outstanding shares of the Company’s
common stock, and the Exercise Price shall be proportionately decreased.

 

    	7

    	 

    

 

6.1.2          Aggregation
of Shares. If, after the date hereof, and subject to the provisions of Section 6.3 below, the number of outstanding shares
of the Company’s common stock is decreased by a consolidation, combination or reclassification of shares of the Company’s
common stock or other similar event, then, on the effective date thereof, the number of shares of the Company’s common stock
purchasable hereunder shall be decreased in proportion to such decrease in outstanding shares of the Company’s common stock,
and the Exercise Price shall be proportionately increased.

 

6.1.3          Replacement
of Securities upon Reorganization, etc. In case of any reclassification or reorganization of the outstanding shares of the
Company’s common stock other than a change covered by Section 6.1.1 or 6.1.2 hereof or that solely affects the par value
of such shares, or in the case of any share reconstruction or amalgamation or consolidation of the Company with or into another
corporation (other than a consolidation or share reconstruction or amalgamation in which the Company is the continuing corporation
and that does not result in any reclassification or reorganization of the outstanding shares of the Company’s common stock),
or in the case of any sale or conveyance to another corporation or entity of the property of the Company as an entirety or substantially
as an entirety in connection with which the Company is dissolved, the Holder of this Purchase Warrant shall have the right thereafter
(until the expiration of the right of exercise of this Purchase Warrant) to receive upon the exercise hereof, for the same aggregate
Exercise Price payable hereunder immediately prior to such event, the kind and amount of shares of stock or other securities or
property (including cash) receivable upon such reclassification, reorganization, share reconstruction or amalgamation, or consolidation,
or upon a dissolution following any such sale or transfer, by a Holder of the number of shares of the Company’s common stock
obtainable upon exercise of this Purchase Warrant immediately prior to such event; and if any reclassification also results in
a change in shares of the Company’s common stock covered by Section 6.1.1 or 6.1.2, then such adjustment shall be made pursuant
to Sections 6.1.1, 6.1.2 and this Section 6.1.3. The provisions of this Section 6.1.3 shall similarly apply to successive reclassifications,
reorganizations, share reconstructions or amalgamations, or consolidations, sales or other transfers.

 

6.1.4          Changes
in Form of Purchase Warrant. This form of Purchase Warrant need not be changed because of any change pursuant to this Section
6.1, and Purchase Warrants issued after such change may state the same Exercise Price and the same number of Shares as are stated
in this Purchase Warrants. The acceptance by any Holder of the issuance of new Purchase Warrants reflecting a required or permissive
change shall not be deemed to waive any rights to an adjustment occurring after the Commencement Date or the computation thereof.

 

6.2          Substitute
Purchase Warrant. In case of any consolidation of the Company with, or share reconstruction or amalgamation of the Company
with or into, another corporation (other than a consolidation or share reconstruction or amalgamation which does not result in
any reclassification or change of the outstanding shares of the Company’s common stock), the corporation formed by such consolidation
or share reconstruction or amalgamation shall execute and deliver to the Holder a supplemental Purchase Warrant providing that
the holder of each Purchase Warrant then outstanding or to be outstanding shall have the right thereafter (until the stated expiration
of such Purchase Warrant) to receive, upon exercise of such Purchase Warrant, the kind and amount of shares of stock and other
securities and property receivable upon such consolidation or share reconstruction or amalgamation, by a holder of the number of
shares of the Company’s common stock for which such Purchase Warrant might have been exercised immediately prior to such
consolidation, share reconstruction or amalgamation, sale or transfer. Such supplemental Purchase Warrant shall provide for adjustments
which shall be identical to the adjustments provided for in this Section 6. The above provision of this Section shall similarly
apply to successive consolidations or share reconstructions or amalgamations.

 

    	8

    	 

    

 

6.3          Elimination of Fractional
Interests. The Company shall not be required to issue certificates representing fractions of Shares upon the exercise of the
Purchase Warrant, nor shall it be required to issue scrip or pay cash in lieu of any fractional interests, it being the intent
of the parties that all fractional interests shall be eliminated by rounding any fraction up or down, as the case may be, to the
nearest whole number of Shares or other securities, properties or rights.

 

7.          Reservation and Listing.
The Company shall at all times reserve and keep available out of its shares of authorized capital stock , solely for the purpose
of issuance upon exercise of the Purchase Warrants, such number of Shares or other securities, properties or rights as shall be
issuable upon the exercise thereof. The Company covenants and agrees that, upon exercise of the Purchase Warrants and payment of
the Exercise Price therefor, in accordance with the terms hereby, all Shares and other securities issuable upon such exercise shall
be duly and validly issued, fully paid and non-assessable and not subject to preemptive rights of any shareholder. The Company
further covenants and agrees that upon exercise of the Purchase Warrants and payment of the exercise price therefor, all Shares
and other securities issuable upon such exercise shall be duly and validly issued, fully paid and non-assessable and not subject
to preemptive rights of any shareholder. As long as the Purchase Warrants shall be outstanding, the Company shall use its commercially
reasonable efforts to cause all shares of the Company’s common stock to be listed (subject to official notice of issuance)
on all national securities exchanges (or, if applicable, on the OTC Bulletin Board or any successor trading market) on which the
shares of common stock issued to the public in the Company’s initial public offering may then be listed and/or quoted.

 

8.          Certain Notice Requirements.

 

8.1          Holder’s
Right to Receive Notice. Nothing herein shall be construed as conferring upon the Holders the right to vote or consent or to
receive notice as a shareholder for the election of directors or any other matter, or as having any rights whatsoever as a shareholder
of the Company. If, however, at any time prior to the expiration of the Purchase Warrants and their exercise, any of the events
described in Section 8.2 shall occur, then, in one or more of said events, the Company shall give written notice of such event
at least fifteen days prior to the date fixed as a record date or the date of closing the transfer books for the determination
of the shareholders entitled to such dividend, distribution, conversion or exchange of securities or subscription rights, or entitled
to vote on such proposed dissolution, liquidation, winding up or sale. Such notice shall specify such record date or the date of
the closing of the transfer books, as the case may be. Notwithstanding the foregoing, the Company shall deliver to each Holder
a copy of each notice given to the other shareholders of the Company at the same time and in the same manner that such notice is
given to the shareholders.

 

8.2          Events Requiring
Notice. The Company shall be required to give the notice described in this Section 8 upon one or more of the following events:
(i) if the Company shall take a record of the holders of shares of the Company’s common stock for the purpose of entitling
them to receive a dividend or distribution payable otherwise than in cash, or a cash dividend or distribution payable otherwise
than out of retained earnings, as indicated by the accounting treatment of such dividend or distribution on the books of the Company,
(ii) the Company shall offer to all the holders of shares of the Company’s common stock any additional shares of capital
stock of the Company or securities convertible into or exchangeable for shares of capital stock of the Company, or any option,
right or warrant to subscribe therefor, or (iii) a dissolution, liquidation or winding up of the Company (other than in connection
with a consolidation or share reconstruction or amalgamation) or a sale of all or substantially all of its property, assets and
business shall be proposed.

 

    	9

    	 

    

 

8.3          Notice of
Change in Exercise Price. The Company shall, promptly after an event requiring a change in the Exercise Price pursuant to Section
6 hereof, send notice to the Holders of such event and change (“Price Notice”). The Price Notice shall describe
the event causing the change and the method of calculating same and shall be certified as being true and accurate by the Company’s
Chief Financial Officer.

 

8.4          Transmittal
of Notices. All notices, requests, consents and other communications under this Purchase Warrant shall be in writing and shall
be deemed to have been duly made when hand delivered, or mailed by express mail or private courier service: (i) if to the registered
Holder of the Purchase Warrant, to the address of such Holder as shown on the books of the Company, or (ii) if to the Company,
to following address or to such other address as the Company may designate by notice to the Holders:

 

If to the Holder:

 

Aegis Capital Corp.

810 Seventh Avenue, 11th Floor

New York, New York 10019

Attention: David Bocchi, Head of Investment Banking

Fax No.: (212) 813-1047

with a copy (which shall not constitute notice) to:

Sichenzia Ross Friedman Ference LLP

61 Broadway, 32nd Floor

New York, New York 10006

Attention: Gregory Sichenzia, Esq.

Fax No: (212) 930-9725

 

If to the Company:

 

CollabRx, Inc.

44 Montgomery Street, Suite 800

San Francisco, California 94104

Attention: Thomas R. Mika, Chief Executive Officer

Fax No: (415)
248-5351

with a copy (which shall not constitute notice) to:

 

Goodwin Procter, LLP

135 Commonwealth Drive

Menlo Park, California 94025-1105

Attention: William C. Davisson, Esq.

Fax No: (650) 853-1038

 

    	10

    	 

    

 

9.          Miscellaneous.

 

9.1          Amendments.
The Company and Aegis may from time to time supplement or amend this Purchase Warrant without the approval of any of the Holders
in order to cure any ambiguity, to correct or supplement any provision contained herein that may be defective or inconsistent with
any other provisions herein, or to make any other provisions in regard to matters or questions arising hereunder that the Company
and Aegis may deem necessary or desirable and that the Company and Aegis deem shall not adversely affect the interest of the Holders.
All other modifications or amendments shall require the written consent of and be signed by the party against whom enforcement
of the modification or amendment is sought.

 

9.2          Headings.
The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the
meaning or interpretation of any of the terms or provisions of this Purchase Warrant.

 

9.3          Entire
Agreement. This Purchase Warrant (together with the other agreements and documents being delivered pursuant to or in connection
with this Purchase Warrant) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof, and
supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter hereof.

 

9.4          Binding
Effect. This Purchase Warrant shall inure solely to the benefit of and shall be binding upon, the Holder and the Company and
their permitted assignees, respective successors, legal representative and assigns, and no other person shall have or be construed
to have any legal or equitable right, remedy or claim under or in respect of or by virtue of this Purchase Warrant or any provisions
herein contained.

 

9.5          Governing
Law; Submission to Jurisdiction; Trial by Jury. This Purchase Warrant shall be governed by and construed and enforced in accordance
with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company hereby agrees
that any action, proceeding or claim against it arising out of, or relating in any way to this Purchase Warrant shall be brought
and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District
of New York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any
objection to such exclusive jurisdiction and that such courts represent an inconvenient forum. Any process or summons to be served
upon the Company may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage
prepaid, addressed to it at the address set forth in Section 8 hereof. Such mailing shall be deemed personal service and shall
be legal and binding upon the Company in any action, proceeding or claim. The Company and the Holder agree that the prevailing
party(ies) in any such action shall be entitled to recover from the other party(ies) all of its reasonable attorneys’ fees
and expenses relating to such action or proceeding and/or incurred in connection with the preparation therefor. The Company (on
its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and the Holder hereby
irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding
arising out of or relating to this Agreement or the transactions contemplated hereby.

 

    	11

    	 

    

 

9.6          Waiver,
etc. The failure of the Company or the Holder to at any time enforce any of the provisions of this Purchase Warrant shall not
be deemed or construed to be a waiver of any such provision, nor to in any way affect the validity of this Purchase Warrant or
any provision hereof or the right of the Company or any Holder to thereafter enforce each and every provision of this Purchase
Warrant. No waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Purchase Warrant shall be
effective unless set forth in a written instrument executed by the party or parties against whom or which enforcement of such waiver
is sought; and no waiver of any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any
other or subsequent breach, non-compliance or non-fulfillment.

 

9.7          Execution
in Counterparts. This Purchase Warrant may be executed in one or more counterparts, and by the different parties hereto in
separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute one and
the same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and
delivered to each of the other parties hereto. Such counterparts may be delivered by facsimile transmission or other electronic
transmission.

 

9.8          Exchange
Agreement. As a condition of the Holder’s receipt and acceptance of this Purchase Warrant, Holder agrees that, at any
time prior to the complete exercise of this Purchase Warrant by Holder, if the Company and Aegis enter into an agreement (“Exchange
Agreement”) pursuant to which they agree that all outstanding Purchase Warrants will be exchanged for securities or cash
or a combination of both, then Holder shall agree to such exchange and become a party to the Exchange Agreement.

 

[Signature Page
Follows]

 

    	12

    	 

    

 

IN WITNESS WHEREOF, the Company has caused
this Purchase Warrant to be signed by its duly authorized officer as of the ____ day of _______, 2014.

	 	COLLABRX, INC.	 
	 	 	 	 
	 	By: 	 	 
	 	Name: 	 	 
	 	Title:	 	 

 

    	13

    	 

    

 

[Form to be used to exercise Purchase
Warrant]

 

 

 

Date: __________, 20___

 

 

 

The undersigned
hereby elects irrevocably to exercise the Purchase Warrant for ______ shares of common stock, par value $0.01 per share (the “Shares”),
of CollabRx, Inc., a Delaware corporation (the “Company”), and hereby makes payment of $____ (at the rate of
$____ per Share) in payment of the Exercise Price pursuant thereto. Please issue the Shares as to which this Purchase Warrant is
exercised in accordance with the instructions given below and, if applicable, a new Purchase Warrant representing the number of
Shares for which this Purchase Warrant has not been exercised.

 

or

 

The undersigned
hereby elects irrevocably to convert its right to purchase ___ Shares of the Company under the Purchase Warrant for ______ Shares,
as determined in accordance with the following formula:

 

	 	X	=	Y(A-B)	 
	 	A	 

 

	Where,	 	 	 
	 	X	=	The number of Shares to be issued to Holder;
	 	Y	=	The number of Shares for which the Purchase Warrant is being exercised;
	 	A	=	The fair market value of one Share which is equal to $_____; and
	 	B	=	The Exercise Price which is equal to $______ per share

The undersigned
agrees and acknowledges that the calculation set forth above is subject to confirmation by the Company and any disagreement with
respect to the calculation shall be resolved by the Company in its sole discretion.

 

Please issue
the Shares as to which this Purchase Warrant is exercised in accordance with the instructions given below and, if applicable, a
new Purchase Warrant representing the number of Shares for which this Purchase Warrant has not been converted.

 

 

Signature                                                                                                        

 

 

 

Signature Guaranteed
                                                                                 

 

    	14

    	 

    

 

INSTRUCTIONS FOR REGISTRATION OF SECURITIES

 

	Name: 	 	 
	 	(Print in Block Letters)	 
	 	 	 
	Address: 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

NOTICE: The signature
to this form must correspond with the name as written upon the face of the Purchase Warrant without alteration or enlargement or
any change whatsoever, and must be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership
on a registered national securities exchange.

 

    	15

    	 

    

 

[Form to be used to assign Purchase Warrant]

 

ASSIGNMENT

 

(To be executed by the registered Holder
to effect a transfer of the within Purchase Warrant): 

 

FOR VALUE RECEIVED, __________________
does hereby sell, assign and transfer unto the right to purchase shares of common stock, par value $0.01 per share, of CollabRx,
Inc., a Delaware corporation (the “Company”), evidenced by the Purchase Warrant and does hereby authorize the
Company to transfer such right on the books of the Company.

  

 

Dated: __________, 20__

 

 

Signature                                                                                            

 

 

Signature Guaranteed                                                                       

 

 

NOTICE: The signature to this form must correspond with the
name as written upon the face of the within Purchase Warrant without alteration or enlargement or any change whatsoever, and must
be guaranteed by a bank, other than a savings bank, or by a trust company or by a firm having membership on a registered national
securities exchange.

 

    	16

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]